SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  1  
 
 
 
 
A Phase 3, Randomized, Double -Blinded Study to 
Evaluate the Safety and Immunogenicity of Omicron 
Subvariant  and Bivalent  SARS -CoV -2 rS Vaccines  in 
Adolescents Previously Vaccinated with mRNA 
COVID -19 Vaccines  
Phase  3 Adolescent  Study  for SARS -CoV -2 rS Variant  Vaccines  
 
Investigational  Products  Monovalent  SARS -CoV -2 Omicron  XBB.1.5  subvariant  vaccine 
(NVX -CoV2601).  
Bivalent  prototype  (Wuhan -Hu-1) and Omicron  XBB.1.5  subvariant  vaccine 
(site-mixed NVX -CoV2373 + NVX -CoV2601).  
Protocol  Number  2019nCoV -314 
Clinical  Trial  Registry 
Identifiers  [STUDY_ID_REMOVED]  
Version  Number  4.0 
Version  Date  21 August  2023  
Version  Amendment  2 
Sponsor  Novavax,  Inc 
21 Firstfield  Road  
Gaithersburg,  MD 20878 
United States  
 
Confidentiality  Statement  
 
The information in this document is considered privileged and confidential by Novavax, Inc., 
and may not be disclosed  to others  except  to the extent  necessary  to obtain  Institutional  Review 
Board (IRB)  approval and informed consent, or as required by national and local laws. Persons 
to whom this information is disclosed must be informed that this information is privileged and 
confidential and that it should not be further disclosed.  

SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  2  
STATEMENT  OF COMPLIANCE  
The study will be conducted in compliance with this clinical study protocol, Good Clinical 
Practices (GCP) as outlined by International Council for Harmonisation (ICH) E6(R2), and all 
applicable  local  and national  regulatory  requirements.  Enrollment  at any clinical  study  site may 
not begin prior to that site receiving approval from the ethics committee of record for the 
protocol and all materials provided to potential participants.  
Any amendments  to the protocol  or changes  to the consent  document  will be approved  before 
implementation of that amendment. Reconsent of previously enrolled participants may be 
necessary depending on the nature of the amendment.  
The Principal Investigator  will ensure  that changes to  the study  plan as defined  by this protocol 
will not be made  without  prior  agreement  from  the Sponsor  and documented  approval from  the 
ethics  committee  of record,  unless  such a change  is necessary  to eliminate  an immediate  hazard 
to the study participants.  
All personnel  involved  in the conduct  of this study  have  completed  Human  Subjects  Protection 
and GCP Training as outlined by their governing institution.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  3  
 
 
SPONSOR’S  APPROVAL  
 
Title  A Phase 3, Randomized, Double -Blinded Study to Evaluate the Safety and 
Immunogenicity of Omicron Subvariant and Bivalent SARS -CoV -2 rS Vaccines  in 
Adolescents Previously Vaccinated with mRNA COVID -19 Vaccines  
Protocol  Number  2019nCoV -314 
Version  Number  4.0 
Version  Date  21 August  2023  
Amendment  Amendment  2 
The design  of this study  as outlined  by this protocol has been  reviewed  and approved  by the 
Sponsor’s  responsible  personnel as  indicated  in the signature  table  below.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Medical  Representative  
Name:  Title:  Signature/Date:  
 
  
  
 
Clinical  Operations  Representative  
Name:  Title:  Signature/Date:  
  
  
 
 

SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  4  
 
INVESTIGATOR’S  AGREEMENT  
I have  read the protocol,  appendices,  and accessory  materials  related  to Study  2019nCoV -314 
and agree to the following:  
• To conduct  this study  as described  by the protocol  and any accessory  materials.  
• To protect  the rights,  safety,  and welfare  of the participants  under  my care. 
• To provide  oversight  to all personnel  to whom  study  activities  have  been delegated.  
• To control  all investigational  products  provided  by the Sponsor  and maintain  records  of 
the disposition of those products.  
• To conduct  the study  in accordance  with all applicable  local  and national  regulations,  the 
requirements of the ethics committee of record for my clinical site, and Good Clinical 
Practices as outlined by ICH E6(R2).  
• To obtain  approval  for the protocol  and written  materials  provided  to participants  prior  to 
initiating the study at my site.  
• To obtain informed consent – and updated consent in the event of new information or 
amendments – from all participants enrolled at my study site prior to initiating any 
study -specific  procedures  or administering  investigational  products  to those  participants  
• To maintain  records  of each participant’s  participation  and all data required  by the 
protocol.  
 
 
 
Name  Title  Institution  
   
Signature  Date  
  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  5  
SUMMARY  OF CHANGES  
Version 1.0 and Version 2.0 of the protocol were signed and approved internally but were not 
released  externally.  The changes  to Amendment  1.0 Version  3.0 incorporated  in Amendment  2.0 
Version 4.0 of the protocol, dated 21 August 2023 are summarized in the table below. Editorial 
and formatting changes are not included in this summary.  
 
Section  Number  Summary  of Change  Rationale  for Change  
Section  1.1 Table  1 Schedule  of 
Events  
Section  6.1.2.2  Day 0 – On-site 
Study Vaccination  
Section 6.1.2.3 Day 28 – In- 
person/Home Health Care 
Follow -up Visit  (-1 to + 7 Days)  
Section  1 Synopsis  Exploratory 
Objectives and Corresponding 
Endpoints  
Section  3 Objectives  and 
Endpoints Table 2  
Section  9.2.4.4  Mucosal  hACE2 
Receptor Binding Inhibition 
Assay Subset  
9.3.2.3  Analysis  of Exploratory 
Immunogenicity Endpoints  Specify  terminology:  SARS -CoV -2 
mucosal IgA -mediated hACE2 
receptor binding inhibition and/or 
antibody responses in a mucosal 
IgA-mediated hACE2 receptor 
binding inhibition assay.  Clarify  that the hACE2  receptor 
binding inhibition assay is a 
mucosal IgA -mediated assay.  
Section 6.1.1.2 
Unscheduled  Study  Visits 
Section 6.1.2.8.2  
Unscheduled  Visit  due to 
Suspected COVID -19 …must contact the site within 3 
days of symptom onset. If possible, 
the participant  should  be brought  in 
for an in -person visit to help gather 
vital signs and do any necessary 
work up inclusive of physical 
examination .…Only in situations  
where the participant cannot come 
in, should a telehealth visit be 
planned.  must  contact  sites within  3 
days of symptom onset for an  
unscheduled telehealth visit due to  
suspected COVID 19. To clarify  that whenever  possible 
an on-site rather  than a telehealth 
visit will be conducted for 
participants with suspected 
COVID -19 illness.  
Section 7.4.1 
Prohibited  Therapies  Topical tacrolimus and ocular 
cyclosporine are permitted.  Use of  
inhaled glucocorticoids is  
prohibited.  Rabies  immune  globulin 
should  be administered  if medically 
indicated.  Reference  to prohibited  use of 
inhaled glucocorticoids was 
removed.  
Abbreviations:  COVID -19 = coronavirus  disease  2019;  hACE2  = human  angiotensin -converting  enzyme  2; 
IgA = Immunoglobulin A; SARS -CoV -2 = severe acute respiratory syndrome coronavirus 2.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  6  
TABLE  OF CONTENTS  
STATEMENT  OF COMPLIANCE  ................................ ................................ ...............................  2 
SPONSOR’S  APPROVAL  ................................ ................................ ................................ ............  3 
INVESTIGATOR’S  AGREEMENT  ................................ ................................ .............................  4 
SUMMARY  OF CHANGES  ................................ ................................ ................................ .........  5 
LIST  OF TABLES  ................................ ................................ ................................ .......................  10 
LIST  OF FIGURES  ................................ ................................ ................................ ......................  10 
LIST  OF APPENDICES  ................................ ................................ ................................ ..............  10 
LIST  OF ABBREVIATIONS  ................................ ................................ ................................ ...... 11 
1 SYNOPSIS  ................................ ................................ ................................ ..........................  14 
1.1 Schedule  of Events  ................................ ................................ ................................ ...........  17 
2 INTRODUCTION  ................................ ................................ ................................ ...............  21 
2.1 Background  ................................ ................................ ................................ ......................  21 
2.1.1 Description  of SARS -CoV -2 Recombinant  Spike  Protein  Nanoparticle  Vaccines  ....... 22 
2.1.2 Supportive  Nonclinical  Data ................................ ................................ .........................  22 
2.1.3 Supportive  Clinical  Data ................................ ................................ ...............................  23 
2.1.3.1  Clinical  Pharmacology  and Safety  ................................ ................................ .............  23 
2.1.4 Benefit:  Risk Assessment  ................................ ................................ ..............................  26 
2.2 Study  Rationale  ................................ ................................ ................................ ................  27 
3 OBJECTIVES  AND  ENDPOINTS  ................................ ................................ .....................  28 
4 STUDY  PLAN  ................................ ................................ ................................ ....................  30 
4.1.1 Study Schematic  ................................ ................................ ................................ ............  30 
4.1.2 Study Design  ................................ ................................ ................................ .................  30 
4.1.3 Design  Rationale  ................................ ................................ ................................ ...........  31 
5 POPULATION  ................................ ................................ ................................ ....................  31 
5.1 Recruitment  ................................ ................................ ................................ ......................  31 
5.1.1 Definitions  ................................ ................................ ................................ .....................  31 
5.1.2 Inclusion  Criteria  ................................ ................................ ................................ ...........  32 
5.1.3 Exclusion  Criteria  ................................ ................................ ................................ ..........  33 
5.2 Other  Considerations  for Eligibility  Criteria  ................................ ................................ .... 34 
6 STUDY  CONDUCT  ................................ ................................ ................................ ...........  35 
6.1 Study Summary  ................................ ................................ ................................ ................  35 
6.1.1 Scheduled  Study  Visits  ................................ ................................ ................................ . 35 
6.1.1.1  Scheduled  Study  Visits  ................................ ................................ ..............................  35 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  7  
6.1.1.2  Unscheduled  Study  Visits  ................................ ................................ ..........................  36 
6.1.1.3  COVID -19 Monitoring  and Assessment  of Severity  ................................ .................  36 
6.1.2 Study Procedures  ................................ ................................ ................................ ...........  37 
6.1.2.1  Screening  Period  ................................ ................................ ................................ ........  37 
6.1.2.2  Day 0 – On-site Study  Vaccination  ................................ ................................ ............  38 
6.1.2.3  Day 28 – In-person/Home  Health  Care  Follow -up Visit  (-1 to + 7 Days)  .................  39 
6.1.2.4  Day 56 – Phone  Follow -up Visit  (± 7 Days)  ................................ ..............................  39 
6.1.2.5  Day 90 – In-person/Home  Health  Care  Follow -up Visit  (± 7 Days)  .........................  40 
6.1.2.6  Day 118 – Phone  Follow -up Visit  (± 7 Days)  ................................ ............................  40 
6.1.2.7  Day 146 – Phone  Follow -up Visit  (± 15 Days)  ................................ ..........................  40 
6.1.2.8  Unscheduled  Visit  ................................ ................................ ................................ ...... 41 
6.1.2.9  Day 180 – End of Study  In-person/Home  Health  Care  Visit  (± 15 Days)  .................  41 
6.2 Immunogenicity  Assessments  ................................ ................................ ..........................  42 
6.3 Discontinuation  or Withdrawal  ................................ ................................ ........................  43 
6.3.1 Individual  Participants  ................................ ................................ ................................ ... 43 
6.3.1.1  Withdrawal  from  Study.  ................................ ................................ .............................  43 
6.3.1.2  Replacement  of Participants  ................................ ................................ .......................  43 
6.3.1.3  Participants  Lost to Follow -up ................................ ................................ ...................  43 
6.3.1.4  Study  Vaccination  Pause  Rules  ................................ ................................ ..................  44 
6.4 Study Termination  ................................ ................................ ................................ ............  44 
7 STUDY  INTERVENTIONS  ................................ ................................ ...............................  45 
7.1 Description  of Products  ................................ ................................ ................................ .... 45 
7.1.1 NVX -CoV2601  (5 µg) ................................ ................................ ................................ .. 45 
7.1.1.1  Formulation,  Storage,  Preparation,  and Handling  ................................ ......................  45 
7.1.1.2  Dosing  and Administration  ................................ ................................ ........................  45 
7.1.2 Prototype/XBB.1.5  Bivalent  Vaccine  (5 µg [Total])  ................................ ....................  45 
7.1.2.1  Formulation,  Storage,  Preparation,  and Handling  ................................ ......................  45 
7.1.2.2  Dosing  and Administration  ................................ ................................ ........................  46 
7.2 Treatment  Assignment  and Bias Minimization  ................................ ................................  46 
7.2.1 Treatment  Allocation  ................................ ................................ ................................ ..... 46 
7.2.2 Randomization  Strategy  and Procedure  ................................ ................................ ........  46 
7.2.3 Extent  and Maintenance of  Blinding  ................................ ................................ .............  47 
7.2.4 Unblinding  Procedures  ................................ ................................ ................................ .. 47 
7.2.4.1  Planned  Unblinding  ................................ ................................ ................................ .... 47 
7.2.4.2  Unplanned  or Unintentional  Unblinding  ................................ ................................ .... 47 
7.3 Assessment  and Verification  of Compliance  ................................ ................................ ... 48 
7.4 Prior  and Concomitant  Therapies  ................................ ................................ .....................  48 
7.4.1 Prohibited  Therapies  ................................ ................................ ................................ ..... 48 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  8  
8 SAFETY  MONITORING  ................................ ................................ ................................ ... 49 
8.1 Definitions  ................................ ................................ ................................ ........................  49 
8.2 Documenting  Adverse  Events  ................................ ................................ ..........................  51 
8.2.1 Details  of the Adverse  Event  ................................ ................................ .........................  52 
8.2.1.1  Assessment  of Causality  ................................ ................................ .............................  52 
8.2.1.2  Action  Taken  with Study  Vaccine  Due to Adverse Event  ................................ .........  52 
8.2.1.3  Other  Action  Taken  ................................ ................................ ................................ .... 53 
8.2.1.4  AE Outcome  ................................ ................................ ................................ ...............  53 
8.2.2 Time  Frame  for Collection  ................................ ................................ ............................  53 
8.2.3 Classification  of Events  ................................ ................................ ................................ . 54 
8.2.3.1  Treatment -Emergent  Adverse  Events  ................................ ................................ ........  54 
8.2.3.2  Adverse  Events  of Special  Interest  ................................ ................................ .............  54 
8.2.3.3  Medically  Attended  Adverse  Events  ................................ ................................ ..........  56 
8.2.3.4  Reactogenicity  Symptoms  ................................ ................................ ..........................  56 
8.3 Reporting  Adverse  Events  ................................ ................................ ................................  57 
8.3.1 Safety  Reporting  to Health  Authorities,  Independent  Ethics  
Committees/Institutional  Review  Boards,  and Investigators  ................................ ........  58 
8.3.2 24/7 Medical  Emergency  Coverage  for Urgent  Protocol -related  Medical  
Questions  ................................ ................................ ................................ .......................  58 
8.4 Pregnancy  ................................ ................................ ................................ .........................  58 
8.5 Overdose  or Misuse  ................................ ................................ ................................ ..........  59 
9 ANALYSIS  ................................ ................................ ................................ .........................  59 
9.1 Sample  Size Calculations  ................................ ................................ ................................ . 59 
9.2 Analysis  Sets ................................ ................................ ................................ ....................  59 
9.2.1 All Randomized  Participants  Analysis  Set ................................ ................................ .... 60 
9.2.2 Full Analysis  Set ................................ ................................ ................................ ...........  60 
9.2.3 Safety  Analysis  Set................................ ................................ ................................ ........  60 
9.2.4 Per-Protocol  Analysis  Set ................................ ................................ ..............................  60 
9.2.4.1  Anti-S Protein  IgG Serology  Subset  ................................ ................................ ..........  60 
9.2.4.2  Neutralization  Assay  Subset ................................ ................................ .......................  60 
9.2.4.3  hACE2  Receptor -Binding  Inhibition  Assay  Subset  ................................ ...................  60 
9.2.4.4  Mucosal  hACE2  Receptor  Binding  Inhibition  Assay  Subset  ................................ ..... 61 
9.3 Analyses  to be Performed  ................................ ................................ ................................  61 
9.3.1 Safety  Analysis  ................................ ................................ ................................ ..............  61 
9.3.1.1  Solicited  Adverse  Events  ................................ ................................ ...........................  61 
9.3.1.2  Unsolicited  Adverse  Events  ................................ ................................ .......................  61 
9.3.1.3  Prior  and Concomitant  Medications  and Vaccinations  ................................ ..............  61 
9.3.1.4  Extent  of Exposure  ................................ ................................ ................................ ..... 62 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  9  
9.3.1.5  Vital  Sign Measurements  and Physical  Examination  ................................ .................  62 
9.3.2 Immunogenicity  Analysis  ................................ ................................ .............................  62 
9.3.2.1  Analysis  of Primary  Immunogenicity  Endpoints  ................................ .......................  62 
9.3.2.2  Analysis  of Secondary Immunogenicity  Endpoints  ................................ ...................  63 
9.3.2.3  Analysis  of Exploratory  Immunogenicity  Endpoints  ................................ .................  63 
9.3.3 Other  Exploratory  Analyses  ................................ ................................ ..........................  64 
9.4 Other  Statistical  Considerations  ................................ ................................ .......................  64 
9.4.1 Population  Analysis  ................................ ................................ ................................ ...... 64 
9.4.1.1  Disposition  and Protocol  Compliance  ................................ ................................ ........  64 
9.4.1.2  Demographics  and Baseline  Characteristics  ................................ ..............................  64 
9.4.1.3  Listings  of Population  Analysis  data ................................ ................................ ..........  65 
9.5 Planned  Interim  Analyses  ................................ ................................ ................................ . 65 
9.6 Specified  Analyses for  Independent  Data  Monitoring  Committee  Review  .....................  65 
9.7 Procedures  for Reporting Changes  to the Planned  Analysis  ................................ ............  65 
10 ETHICAL  CONSIDERATIONS  ................................ ................................ ........................  65 
10.1 Good  Clinical  Practice  ................................ ................................ ................................ ..... 65 
10.2 Ethics  Review  ................................ ................................ ................................ ...................  65 
10.3 Informed  Consent  ................................ ................................ ................................ .............  66 
10.4 Data  Privacy  ................................ ................................ ................................ .....................  66 
11 OVERSIGHT  ................................ ................................ ................................ ......................  67 
11.1 Quality  Control  and Assurance  ................................ ................................ ........................  67 
11.1.1  Monitoring  ................................ ................................ ................................ .....................  67 
11.1.2  Audits  ................................ ................................ ................................ ............................  68 
11.1.3  Protocol  Deviations  ................................ ................................ ................................ ....... 68 
11.1.4  Records  ................................ ................................ ................................ ..........................  68 
11.1.4.1  Data  Capture  and Management  ................................ ................................ ..................  68 
11.1.4.2  Source  Documentation  ................................ ................................ ...............................  69 
11.1.4.3  Records  Retention  ................................ ................................ ................................ ...... 69 
11.2 Study  Termination  or Study  Site Closure  ................................ ................................ ........  69 
12 PUBLICATION  POLICY  ................................ ................................ ................................ ... 69 
13 FINANCING  AND  INSURANCE  ................................ ................................ .....................  70 
14 REFERENCES  ................................ ................................ ................................ ....................  71 
15 APPENDICES  ................................ ................................ ................................ .....................  75 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  10  
LIST  OF TABLES  
Table  1: Schedule  of Events  for Study  2019nCoV -314 ................................ .....................  18 
Table  2: Study  2019nCoV -314 Objectives  and Endpoints  ................................ .................  28 
Table  3: Study  Groups  and Treatments  ................................ ................................ ..............  31 
Table  4: Investigational  Treatments  Used  in This Study  ................................ ...................  45 
Table 5:  Case Definitions of Probable and Confirmed Myocarditis, Pericarditis, and  
Myopericarditis  ................................ ................................ ................................ .... 55 
Table 6:  Management of Probable or Confirmed Myocarditis, Pericarditis, and  
Myopericarditis  Cases  ................................ ................................ ..........................  56 
Table  7: Potential  Immune -Mediated  Medical  Conditions  ................................ ................  75 
Table  8: Adverse  Events  Representing  Complications  Specific  to COVID -191 ........................  76 
Table  9: Modified  FDA  Toxicity  Grading  Scale  for Clinical  Abnormalities  (Local  
and General  Systemic  Reactogenicity)  ................................ ................................ . 77 
Table  10: FDA  Toxicity  Grading  Scale  for Clinical  Abnormalities  (Vital  Signs)  ...............  78 
Table  11: COVID -19 Severity  Grading  Criteria  ................................ ................................ .. 79 
 
LIST  OF FIGURES  
Figure  1: Flow  Diagram  for Study 2019nCoV -314 ................................ .............................  30 
 
 
LIST  OF APPENDICES  
Appendix  1: Listings  of Adverse  Events  of Special  Interest  ................................ ....................  75 
Appendix  2: Toxicity  Grading  Scale  for Clinical  Abnormalities  (Local  and General  
Systemic  Reactogenicity  and Vital  Signs)  ................................ ...........................  77 
Appendix  3: Assessment  of COVID -19 Severity  ................................ ................................ ..... 79 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  11  
LIST  OF ABBREVIATIONS  
 
Abbreviation  Definition  
24/7 24 hours  7 days a week  
2019nCoV  Novel  coronavirus  
AE Adverse  event  
AESI  Adverse  event  of special  interest  
AHA  American  Heart  Association  
ANCA  Anti-neutrophil  cytoplasmic  antibody  
AR Adverse  reaction  
BMI Body  mass  index  
CDC  Centers  for Disease  Control  
CI Confidence  interval  
COVID -19 Coronavirus  disease  2019  
CRO  Clinical  research  organization  
ECG  Electrocardiogram  
eCRF  Electronic  case report  form 
EDC  Electronic  data capture  
eDiary  Electronic  participant -reported  outcome  diary  application  
ELISA  Enzyme -linked  immunosorbent  assay  
EOS End of study  
ER Emergency  room  
EU European  Union  
FAS Full Analysis  Set 
FDA  Food  and Drug  Administration  
GCP  Good  Clinical  Practice  
GLP Good  Laboratory  Practice  
GMC  Geometric  mean  concentration  
GMEU  Geometric  mean  ELISA  unit 
GMFR  Geometric  mean  fold rise 
GMT  Geometric  mean  titer 
GMTR  Geometric  mean  titer ratio (between  groups)  
GP Glycoprotein  
hACE2  Human  angiotensin -converting  enzyme  2 
HBV  Hepatitis  B virus  
HEENT  Head,  eyes,  ears, nose,  and throat  
HIV Human  immunodeficiency  virus  
HPV  Human  papilloma  virus  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  12  
 
 
Abbreviation  Definition  
IB Investigator’s  Brochure  
ICF Informed  consent  form 
ICH International  Council  for Harmonisation  
ID50 Inhibitory  dilution  at a concentration  of 50% 
IEC Independent  Ethics  Committee  
IgA Immunoglobulin  A 
IgG Immunoglobulin  G 
IM Intramuscular  
IMP Investigational  medical  product  
IND Investigational  New  Drug  
IRB Institutional  Review  Board  
IWRS  Interactive  Web  Response  System  
LB Lower  bound  
LBCI  Lower  bound  confidence  interval  
LLOQ  Lower  Limit  of Quantitation  
MAAE  Medically  attended  adverse  event  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MERS  Middle  East Respiratory  Syndrome  
MHC  Major  histocompatibility  complex  
mRNA  Messenger  ribonucleic  acid 
NAb  Neutralizing  Antibody  
NVX -CoV2373  Prototype  vaccine  with Matrix -M adjuvant  
NVX -CoV2515  Omicron  BA.1  subvariant  vaccine  with Matrix -M adjuvant  
NVX -CoV2601  Omicron  XBB.1.5  subvariant  vaccine  with Matrix -M adjuvant  
OTC  Over -the-counter  
PCR Polymerase  chain  reaction  
PIMMC  Potential  immune -mediated  medical  conditions  
PP Per-Protocol  
PT Preferred  term 
r Recombinant  
RNA  Ribonucleic  acid 
S Spike  (protein)  
SAE Serious  adverse  event  
SAP Statistical  analysis  plan 
SAR  Suspected  adverse  reaction  
SARS -CoV Severe  acute  respiratory  syndrome  coronavirus  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  13  
 
 
Abbreviation  Definition  
SARS -CoV-2 Severe  acute  respiratory  syndrome  coronavirus  2 
SARS -CoV -2 rS Severe  acute  respiratory  syndrome  coronavirus  2 recombinant  spike  protein 
nanoparticle vaccine  
SCR Seroconversion  rate 
Sf9 Spodoptera  frugiperda  
SII Serum  Institute  of India  
SMC  Safety  Monitoring  Committee  
SOC  System  organ  class 
SOE Schedule  of Events  
SOP Standard  operating  procedure  
Td Tetanus  diphtheria  
Tdap/Dtap  Tetanus,  diphtheria  and pertussis  
TEAE  Treatment -emergent  adverse  event  
UK United  Kingdom  
US United  States  
VOC  Variants  of concern  
VRBPAC  Vaccines  and Related  Biological  Products  Advisory  Committee  
WHO  World  Health  Organization  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  14  
 
 
1 SYNOPSIS  
 
Study  Title  A Phase 3, Randomized, Double -Blinded Study to Evaluate the Safety and 
Immunogenicity  of Omicron  Subvariant  and Bivalent  SARS -CoV -2 rS Vaccines  in 
Adolescents Previously Vaccinated with mRNA COVID -19 Vaccines  
Short  Title  Phase  3 Adolescent  Study  for SARS -CoV -2 rS Variant  Vaccines  
Study  Phase  3 
Study  Design  This is a Phase 3, randomized, double -blinded study to evaluate the safety and 
immunogenicity of booster doses of Omicron subvariant severe acute respiratory 
syndrome  coronavirus  2 (SARS -CoV -2) recombinant  rS spike  (S) protein  nanoparticle 
vaccines (SARS -CoV -2 rS) adjuvanted with Matrix -M™ adjuvant (NVX -CoV2601 
[Omicron XBB.1.5]) and bivalent (NVX -CoV2373 [prototype] + NVX -CoV2601) in 
previously vaccinated adolescent participants ≥ 12 to < 18 years of age.  
Approximately  400 adolescents  who have  received  a regimen  of ≥ 2 doses  of the 
Moderna  and/or  Pfizer -BioNTech  monovalent  and/or  bivalent  COVID -19 vaccines  
≥ 90 days previously  will be randomized  1:1 to Group  A or Group  B: 
• Group  A: 1 dose of NVX -CoV2601  (1 on Day 0) 
• Group  B: 1 dose of bivalent  NVX -CoV2373  + NVX -CoV2601  (1 on Day 0) 
All participants will remain on study for immunogenicity and safety data collection 
through Day 180.  
Rationale  Novavax,  Inc., is developing  recombinant  vaccines  adjuvanted  with the saponin  based 
Matrix -M adjuvant for the prevention of disease caused by SARS -CoV -2. 
Given  the widespread  circulation  of Omicron  subvariants,  regulatory  body  discussions, 
and the associated decreased immunogenicity and efficacy of previously approved 
vaccines based on the prototype Wuhan strain, vaccines based on the Omicron 
subvariant XBB.1.5 (NVX -CoV2601) were developed and are being evaluated for 
safety and immunogenicity. The Omicron subvariant product in this study will also be 
used in combination with a prototype (Wuhan -Hu-1) NVX -CoV2373 in the form of a 
site-mixed bivalent vaccine to  explore the safety and immunogenicity of vaccines 
containing antigen for both the ancestral (Wuhan) and XBB.1.5 subvariant strains of 
SARS -CoV-2. 
This study is designed to assess the safety and immunogenicity of the Novavax 
Omicron  XBB.1.5  subvariant  vaccine  (NVX -CoV2601)  alone  or in combination  with 
the prototype Novavax vaccine (NVX -CoV2373) as a bivalent product in adolescent 
participants ≥ 12 to < 18 years of age who previously received ≥ 2 doses of 
approved/authorized monovalent and/or bivalent mRNA vaccines.  
The safety profile of  the booster dose will be assessed along with its ability to increase 
antibody titers against the Omicron XBB.1.5 subvariant. If favorable safety and 
immunogenicity  profiles  are observed  following  the booster  dose of NVX -CoV2601  or 
the bivalent product, this would support the use of bivalent, variant based vaccines in 
adolescents in the global COVID -19 vaccination effort.  
Target  Population  Medically stable male and non -pregnant female adolescents ≥ 12 to < 18 years of age. 
All participants  will have  received  a regimen  of ≥ 2 doses  of the Moderna  and/or  Pfizer - 
BioNTech COVID -19 monovalent and/or bivalent vaccines ≥ 90 days prior to study 
vaccination.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  15  
 
 
Number of 
Participants  Approximately  400 participants  
Length of 
Participation  On study  (including  screening  and follow -up): 
Up to approximately 194 days (7 months)  
Interventions  1. NVX -CoV2601  (5 µg): Coformulated  Omicron  XBB.1.5  SARS -CoV -2 rS vaccine 
with Matrix -M adjuvant: supplied as a solution for preparation for injection, at a 
concentration  of 10 µg antigen and  100 µg adjuvant per mL. All injections  will be 
administered in a 0.5 mL injection volume at a dose of 5 µg antigen with 50 µg 
Matrix -M adjuvant.  
2. Prototype/XBB.1.5 Bivalent Vaccine (5 µg): A site -mixed bivalent vaccine 
prepared  by combining  0.25 mL of NVX -CoV2373  and 0.25 mL NVX -CoV2601. 
All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg 
total antigen (2.5 µg prototype antigen + 2.5 µg Omicron XBB.1.5 antigen) with 
50 µg Matrix -M adjuvant.  
Primary  Safety 
Objective and 
Endpoints  Objective : To assess the overall safety of 1 heterologous booster dose of 
NVX -CoV2601  and the bivalent  vaccine  (NVX -CoV2373  + NVX -CoV2601). 
Endpoints : 
• Incidence,  duration,  and severity  of solicited  local  and systemic  adverse  events 
(AEs) for 7 days following vaccination.  
• Incidence,  severity,  and relationship  of unsolicited  AEs through  28 days after 
vaccination  
• Incidence  and severity  of medically  attended  adverse  events  (MAAEs)  attributed  to 
study vaccine, adverse events of special interest (AESIs) (predefined list including 
potential immune -mediated medical conditions (PIMMCs), myocarditis and/or 
pericarditis, and complications specific to COVID -19), and serious adverse events 
(SAEs) through day 180 or end of study (EOS).  
Primary 
Immunogenicity 
Objective and 
Endpoints  Objective:  To describe  the neutralizing  antibody  (NAb)  response  induced  by 
NVX -CoV2601  and the bivalent  vaccine  (NVX -CoV2373  + NVX -CoV2601)  against 
the Omicron XBB.1.5 strain.  
• Neutralizing  antibody  (NAb)  geometric  mean  titers  (GMTs)  to the Omicron 
XBB.1.5 strain, assessed at Day 28 following initial study vaccination.  
• NAb  geometric  mean  fold rise (GMFR)  at Day 28 from  baseline  (Day  0). 
Secondary 
Objectives  and 
Corresponding 
Endpoints  Objective : To describe  the NAb  response  induced  by NVX -CoV2601  and the bivalent 
vaccine  (NVX -CoV2373  + NVX -CoV2601)  against  the Omicron  XBB.1.5  strain  over 
time.  
Endpoints : 
• NAb  GMTs  to the Omicron  XBB.1.5  strain  at relevant  time points  (Days  0, 90, and 
180).  
• NAb  GMFR  at relevant  time points  (Days  90, and 180) from  baseline  (Day  0).  
Group  Previous 
Vaccine  Novavax  Vaccine  Booster 
(antigen/adjuvant)   
n 
A ≥ 2 doses 
Moderna 
and/or 
Pfizer - 
BioNTech  NVX -CoV2601  (5 μg/50  μg) 200 
B Bivalent  NVX -CoV2373  + NVX -CoV2601  
(5 μg/50  μg [total])  200 
 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  16  
  
 Objective : To describe  immunoglobulin  G (IgG)  antibody  levels  induced  by 
NVX -CoV2601  and the bivalent  vaccine  (NVX -CoV2373  + NVX -CoV2601)  against 
the Omicron XBB.1.5 strain over time.  
Endpoints : 
• IgG geometric  mean  ELISA  (enzyme  linked  immunosorbent  assay)  units  (GMEUs) 
to the Omicron XBB.1.5 S protein at relevant time points (Days 0, 28, 90, and  
180). Derived/calculated endpoints based on these data will include GMFR.  
Exploratory 
Objectives  and 
Corresponding 
Endpoints  Objective : To describe  the NAb  and IgG antibody  responses  induced  by 
NVX -CoV2601  and the bivalent  vaccine  (NVX -CoV2373  + NVX -CoV2601)  against 
the ancestral (Wuhan) strain over time.  
Endpoints : 
• NAb  titers  and IgG GMEUs  to the ancestral  (Wuhan)  strain  at relevant  time points 
(Days 0, 28, 90, and 180). Derived/calculated endpoints based on these data will 
include GMFR.  
 
Objective : To describe  antibody  responses  in a human  angiotensin  converting  enzyme -2 
(hACE2) receptor binding inhibition assay induced by NVX -CoV2601 and the  bivalent 
vaccine (NVX -CoV2373 + NVX -CoV2601) to the Omicron XBB.1.5 and ancestral 
(Wuhan) strains over time.  
Endpoints : 
• GMTs to the Omicron XBB.1.5 and ancestral (Wuhan) strains at relevant time 
points  (Days  0, 28, 90, and 180).  Derived/calculated  endpoints  based  on these  data 
will include GMFR.  
 
Objective:  To describe  antibody  responses  in a mucosal  IgA-mediated  hACE2  receptor 
binding inhibition assay induced by NVX -CoV2601 and the bivalent vaccine  
(NVX -CoV2373  + NVX -CoV2601)  to the Omicron  XBB.1.5  and ancestral  (Wuhan) 
strains over time.  
Endpoints : 
• GMTs  to the Omicron  XBB.1.5  and ancestral  (Wuhan)  strains  at relevant  time 
points (Days 0 and 28). Derived/calculated endpoints based on these data will 
include GMFR . 
 
Objective:  To utilize  additional  assays  (current  or to be developed)  to better 
characterize the immune response for future vaccine development needs.  
Endpoint : Additional  endpoints  to evaluate  immune  responses  may be developed  based 
on the assays used.  
 
Objective:  To characterize  the severity  of COVID -19 in participants  who become 
infected during the course of the study.  
Endpoint : Detected  case will be characterized  as mild,  moderate,  or severe  as assessed 
using the provided criteria.  
Number  of Sites  Up to 25 sites in the United  States  and Canada  (Canadian  sites contingent  upon 
additional approval).  
Study  Duration  Estimated  duration:  Approximately  7 months  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  17  
 
 
1.1 Schedule of Events  
The schedule  of events  (SOE)  is presented  in Table  1. 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Page  18 Confidential   
Table  1: Schedule  of Events  for Study  2019nCoV -314 
 
Study  Day –14 to 01 01 28 56 90 118 146 180 Unscheduled 
Visit2, 19 Window  (days)3   -1 to + 7 ± 7 ± 7 ± 7 ± 15 ± 15 
Study  Visit  Screening  1 219 3 (Phone)  419 5 (Phone)  6 (Phone)  EOS4, 19 Gen Sp 
Informed  consent  X          
Medical  history5 X          
Inclusion/exclusion  criteria6 X X7         
Demographics8 X          
Prior/concomitant  medications9 X X7 X X X X X X X X 
Vital  sign measurements10 X X7      X X  
Urine  pregnancy  test (POCBP)11 X X7         
Physical  examination12 X X7   X   X X  
Baseline  ECG   X7         
Monitoring  and Assessment  of COVID -19 
Severity13   
X X X X X X   
Nasal  swab  for SARS -CoV -2 (PCR)  – 
anterior nares    
X7        
X 
Oral swab for SARS -CoV -2 (mucosal 
IgA-mediated  hACE2  receptor -binding 
inhibition assay)    
X  
X        
Blood sampling for SARS -CoV -2 
serostatus  (anti N-protein  serology)    
X7 X     
X   
Blood  sampling  for SARS -CoV -2 (ELISA 
for anti S -protein serology)    
X7 X  
X   
X  
X 
Blood  sampling  for SARS -CoV -2 NAb 
assay    
X7 X  
X   
X  
X 
Blood  sampling  for hACE2  receptor - 
binding inhibition assay    
X7 X  
X   
X  
X 
Vaccination14  X         
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Page  19 Confidential   
Table  1: Schedule  of Events  for Study  2019nCoV -314 
 
Study  Day –14 to 01 01 28 56 90 118 146 180 Unscheduled 
Visit2, 19 Window  (days)3   -1 to + 7 ± 7 ± 7 ± 7 ± 15 ± 15 
Study  Visit  Screening  1 219 3 (Phone)  419 5 (Phone)  6 (Phone)  EOS4, 19 Gen Sp 
Reactogenicity/participant  eDiary 
completion14,15  
X         
All unsolicited  AEs  X X      X X 
MAAEs16,17   X X X X X X X X X 
SAEs17 X X X X X X X X X X 
AESI  (including  PIMMCs,  myocarditis 
and/or pericarditis, and complications 
specific to COVID -19)17   
X  
X  
X  
X  
X  
X  
X  
X  
X 
EOS  form18        X   
Abbreviations: AE = adverse event; AESI = adverse event(s) of special interest; BMI = body mass index; ECG = electrocardiogra m; eDiary = electronic 
participant -reported outcome  diary application; ELISA = enzyme -linked immunosorbent assay; EOS  = end of study; Gen = Unscheduled Visit due to a 
general medical issue; hACE2 = human angiotensin -converting enzyme 2; HEENT = head, eye, ear, nose, and throat (examination); ID = identification; 
POCBP = participants of childbearing potential; MAAE = medically attended adverse event; N = nucleocapsid (protein); NAb = ne utralizing antibody; 
OTC  = over-the-counter;  PCR  = polymerase  chain  reaction;  PIMMC  = potential  immune -mediated  medical  conditions;  S = spike  (protein);  SAE  = serious 
adverse event; SAP = statistical analysis plan; SARS -CoV -2 = severe acute  respiratory syndrome coronavirus 2; Sp =  Unscheduled Visit due to suspected 
COVID -19 symptoms.  
1. The Screening  visit and Day 0 visit may be combined  if feasible  at any given  study  site. 
2. An Unscheduled Visit will be conducted by study personnel for safety follow -up for any participant experiencing a medical issue while on study. For 
general  Unscheduled  Visits,  the investigator  may also perform  any of the assessments  listed  in the SOE  if needed  for the clinical  evaluation  of an AE. For 
an Unscheduled Visit due to suspected COVID -19 symptoms, confirmed symptomatic cases of COVID -19 should be recorded as an AE, SAE, or 
COVID -19 relevant AESI as appropriate and the visit may be conducted as a telehealth visit if required by local health regulations.  Positive PCR swab 
results in asymptomatic participants should also be entered as an AE.  
3. Should  a study  pause  occur,  visits/windows  will be adjusted  to allow  participants  to continue  without  protocol  deviation.  
4. EOS  assessments  will be conducted  in person.  Should  participants  decide  to terminate  early,  a telephone  call will occur  to collect  the maximum  safety  data 
possible.  
5. Including  prior  and concomitant  medical  conditions,  all COVID -19 vaccinations,  all other  recent  vaccinations  (≤ 90 days),  and significant  surgical  
procedures.  
6. Specific  exclusions  to study  vaccination  will be assessed  before  any vaccination.  Waivers  for enrolling  participants  with exclusions  will not be given.  
7. Performed  prior  to study  vaccination.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Page  20 Confidential   
Table  1: Schedule  of Events  for Study  2019nCoV -314 
 
Study  Day –14 to 01 01 28 56 90 118 146 180 Unscheduled 
Visit2, 19 Window  (days)3   -1 to + 7 ± 7 ± 7 ± 7 ± 15 ± 15 
Study  Visit  Screening  1 219 3 (Phone)  419 5 (Phone)  6 (Phone)  EOS4, 19 Gen Sp 
8. Screening  only.  Including  age, year of birth,  sex, race,  ethnicity,  weight,  height,  and BMI  (derived).  
9. Prior and concomitant medications, including recent and current medications at the time of screening to be reviewed to ensure  eligibility criteria are 
fulfilled.  Concomitant  medications  include  prescription  and OTC  (including  vaccines  in the past 90 days and all COVID -19 vaccinations)  taken  by the 
participant. Do not record herbals, vitamins, and supplements.  
10. Including  respiratory  rate, blood  pressure,  pulse  rate, pulse  oximetry  and temperature  (oral  or via forehead/ear  reader).  On study  vaccination  days,  vital 
sign measurements will be collected once before study vaccination to ensure participant has no evidence of fever prior to stu dy vaccination.  
11. Participants of childbearing potential only. A urine pregnancy test will be performed at Screening and prior to study vaccina tion. A positive urine 
pregnancy  test at any time will result  in the participant  not receiving  any further  study  vaccination.  A positive  urine  pregnancy  test at Screening  will result 
in screen failure.  
12. Full physical examination at screening to include HEENT, neck, lungs, heart, cardiovascular, abdomen and musculoskeletal syst em/extremities to allow 
for study  vaccination;  symptom -directed  (targeted)  physical  examination  at all other  scheduled  time points.  Full physical  examinations  will be performed 
at any unscheduled visit.  
13. Participants  will be asked  to report  any PCR/rapid  test confirmed  cases  of COVID -19 that occurred  since  last contact.  For all medically  attended  cases  of 
COVID -19, an attempt will be made to obtain all relevant medical records in order to assess case severity.  
14. Following  vaccination,  participants  will remain  in the clinic  or under  study  staff observation  for at least 15 minutes  post-vaccination  to be monitored  for 
any immediate hypersensitivity and anaphylaxis reactions.  
15. Participants  will utilize  an eDiary  to record  reactogenicity  following  vaccination  and for an additional  6 days after vaccination.  All eDiary  entries  will be 
reviewed and assessed by the investigator.  
16. All MAAEs  will be collected  for 28 days following  vaccination.  Only  treatment  related  MAAEs  will be collected  throughout  the duration  of the study.  
17. Details  regarding  the dates  and nature  of any health  encounters  associated  with SAEs,  AESIs,  and/or  MAAEs  that required  a visit with a healthcare 
provider will be collected in the eCRF.  
18. EOS  form  will be completed  for all participants,  including  participants  who are terminated  early.  
19. These  visits  may take place  at the homes  of trial participants  or another  safe, alternative  location  by a professionally  trained  Home  Health  Care  provider.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  21  
 
2 INTRODUCTION  
2.1 Background  
Coronaviruses  are medium  sized,  enveloped,  positive -stranded  ribonucleic  acid (RNA)  viruses, 
with a characteristic crown -like appearance in electron micrographs due to circumferential 
studding of the viral envelope with projections comprising the spike (S) protein. There are  
4 different strains (229E, OC43, NL63, and HKU1), which are ubiquitous in humans and 
generally  result  in mild upper  respiratory  illnesses  and other  common  cold symptoms,  including 
malaise, headache, nasal discharge, sore throat, fever, and cough ( Su 2016 ). In addition, other 
coronavirus  strains  are widespread  in animals,  where  they typically  cause  enteric  disease.  These 
zoonotic coronaviruses have been known to evolve into strains that can infect humans with 
serious consequences, including severe acute respiratory syndrome coronavirus (SARS -CoV) 
from 2002 to 2003, Middle East Respiratory Syndrome (MERS) -CoV since 2012, and most 
recently, the novel SARS -CoV -2 since 2019 ( Habibzadeh 2020 ). 
In late December of 2019, an outbreak of respiratory disease caused by a novel coronavirus 
(2019nCoV) was detected in Wuhan, Hubei province, China. The virus’ rapidly discerned 
genetic relationship with the 2002 -2003 SARS -CoV has resulted in adoption of the name 
“SARS -CoV -2,” with the disease  being  referred  to as Coronavirus  disease  2019  (COVID -19). 
Thereafter,  reports  from  the United  Kingdom  (UK),  Brazil,  India,  and South  Africa  revealed  the 
emergence of the B.1.1.7 (Alpha), P.1 (Gamma), B.1.617.2 (Delta), and B.1.351 (Beta) and  
B.1.1.529 (Omicron) variants of SARS -CoV -2, respectively, with confirmed acquisition of 
mutations in key antigenic sites in the receptor -binding domain and N -terminal domain of the 
spike  (S) protein.  Omicron  subvariants  have  persisted  in circulation,  with the XBB.1.5  subvariant 
accounting for approximately 82% of circulation as of 28 Apr 2023 ( CDC 2022 , CDC 2023 ). 
Current evidence demonstrates that variant strain mutations such as those in the Omicron 
XBB.1.5 sublineage confer the ability to evade both natural and vaccine induced neutralizing 
antibodies ( Qu 2023 , Yue 2023 , Zhang 2022 ). 
Initial  actions  to stay ahead  of SARS -CoV -2 evolution  included  direction  from  the US Food  and 
Drug Administration (FDA) to recommend the development vaccines containing an Omicron 
BA.4/5 component ( Marks 2022 ). On 26 January 2023, the Vaccines and Related Biological 
Products Advisory Committee (VRBPAC) met to discuss further updates to the composition of 
COVID -19 vaccines. At the conclusion of this meeting, the VRBPAC voted to harmonize the 
vaccine strain composition of primary series and booster vaccinations into a single, updated 
composition for the fall 2023 vaccination campaign.  
The present  study  will assess  the safety  and immunogenicity  of an Omicron  XBB.1.5  subvariant 
vaccine (NVX -CoV2601) alone as a monovalent product or in combination with the prototype 
Novavax  vaccine  (NVX -CoV2373)  as a bivalent  product  in an adolescent  population.  The study 
will enroll adolescent participants ≥ 12 to < 18 years of age who have previously received  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  22  
 
≥ 2 doses  of the Moderna  and/or  Pfizer -BioNTech  monovalent  and/or  bivalent  vaccines  
≥ 90 days  prior  to study vaccination.  
2.1.1 Description  of SARS -CoV -2 Recombinant  Spike  Protein  Nanoparticle  Vaccines  
NVX -CoV2373  is the prototype  SARS -CoV -2 rS nanoparticle  vaccine  construct  adjuvanted  with 
Matrix -M adjuvant that is intended to be used for the active immunization for the prevention of 
mild, moderate, and severe COVID -19 caused by SARS -CoV -2. NVX -CoV2373 is constructed 
from the full -length, wild -type SARS -CoV -2 S glycoprotein (GP) based on the GenBank gene 
sequence MN908947, nucleotides 21563 -25384 from the 2019 SARS -CoV -2 genome (Wuhan - 
Hu-1 strain). In the  wake of  emerging SARS -CoV -2 variants, Novavax continues to produce  and 
investigate rS nanoparticle vaccines using the sequenced genomes from several variant strains 
(multiple  potential  sequences  being  evaluated  with one to be down -selected  for final production). 
The S protein from each virus is a type 1 trimeric GP that is produced as an inactive  
S0 precursor.  The S-gene  is then codon -optimized  for expression  in Spodoptera  frugiperda  (Sf9) 
insect cells.  
All SARS -CoV -2 rS vaccines  are adjuvanted  with Matrix -M adjuvant.  Adjuvants  are compounds 
which,  when  combined with  a specific  vaccine  antigen,  serve  to increase  the immune  response  to 
the vaccine. In general, adjuvants work by engaging one or more components of the innate 
immune system. Matrix -M is a saponin -based adjuvant, derived from the bark of the Quillaja 
saponaria Molina tree, which can be co -administered with an antigen to induce a targeted and 
enhanced immune response. The proposed mode of action of Matrix -M adjuvant does not  
include a depot effect, but rather occurs through a combination of activities, including 
recruitment and activation of innate immune cells to the site of vaccine injection, rapid antigen 
delivery to antigen -presenting cells, and enhanced antigen presentation via both major 
histocompatibility complex (MHC) I and MHC II molecules in the draining lymph nodes.  
The investigational  products  used in this study  are manufactured  by Serum  Institute  of India  (SII) 
through a partnership with Novavax. Production of NVX -CoV2601 was initiated based on  
master virus seeds produced and supplied to SII by Novavax. Aside from the differences in 
antigenic composition compared to NVX -CoV2373; the manufacturing process and final 
composition will be the same as for the authorized NVX -CoV2373 vaccine.  
Additional product information, including manufacturing details and supportive clinical and 
nonclinical  study  summaries,  can be found  in the SARS -CoV -2 rS Investigator’s  Brochure  (IB) 
(Novavax 2022 ). 
2.1.2 Supportive  Nonclinical  Data  
Supportive nonclinical data are available through studies conducted for the Novavax 
manufactured  prototype  SARS -CoV -2 rS product  (NVX -CoV2373).  Pharmacological  properties 
of the vaccines used in this study are expected to be equivalent to those produced by Novavax.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  23  
 
Nonclinical  safety,  immunogenicity,  and protective  efficacy  have  now been  confirmed  in Phase  3 
clinical trials. Nonclinical data can be found in the Investigator’s Brochure.  
A good laboratory practice (GLP) -compliant developmental and reproductive toxicity study was 
completed  in Sprague -Dawley  rats. Females  were  immunized  with placebo,  5 µg of SARS -CoV - 
2 rS antigen with 10 µg of Matrix -M adjuvant, or 10 µg of Matrix -M adjuvant alone. These 
doses were approximately 40 -fold in excess of the human dose, on a weight -adjusted basis, in a 
50 kg human female. Doses were given on pre -mating Days 1 and 15, and then, after mating, at 
gestational Days 7 and 15. Dams immunized with antigen plus adjuvant, but not adjuvant alone, 
had strong anti -S immunoglobulin G (IgG) responses, and vaccine -induced antibody was 
transferred transplacentally to the fetuses. Mating and fertility, as well as the number and 
viability of fetuses, were unaffected by adjuvant or complete vaccine. There was no treatment 
effect on fetal malformations or skeletal abnormalities. In dams allowed to deliver, receipt of 
adjuvant or complete vaccine did not affect the gestational duration at delivery or the number of 
live pups; and there was also no impact of the attainment of developmental milestones by pups 
through 21 days of life.  
2.1.3 Supportive  Clinical  Data  
Supportive  clinical  data are available  via studies  conducted  using  Novavax  manufactured 
SARS -CoV -2 rS products.  
As of this date,  clinical  data are available  from  studies  performed  using  NVX -CoV2373  and an 
Omicron BA.1 variant vaccine (NVX -CoV2515).  
The clinical development program for Novavax’s SARS -CoV -2 rS with Matrix -M adjuvant 
primarily comprises 4 clinical studies: a Phase 1 -2 study of SARS -CoV -2 rS with or without 
Matrix -M adjuvant in healthy adult participants 18 to 59 years of age (Study 2019nCoV -101– 
Part 1) and SARS -CoV -2 rS with Matrix -M adjuvant  in healthy  adult  participants  18 to 84 years 
of age (Study 2019nCoV -101 – Part 2); a Phase 2a/b study of SARS -CoV -2 rS with Matrix -M 
adjuvant in healthy adult participants 18 to 84 years of age living without human 
immunodeficiency virus (HIV) and medically stable adult participants 18 to 64 years of age 
living with HIV (Study 2019nCoV -501); and 2 Phase 3 studies in healthy and medically stable 
adult participants ≥ 18 years of age and adolescent participants 12 to < 18 years of age  
(Study  2019nCoV -301) and 18 to 84 years  of age  (Study 2019nCoV -302).  
2.1.3.1  Clinical  Pharmacology  and Safety  
Clinical  data from  Phase  1-2 trials  and additional  clinical  data from  Phase  3 trials  can be found  in 
the Investigator’s Brochure and their respective publications ( Novavax 2022 , Keech 2020 , 
Mallory 2022 , Dunkle 2021 , Heath 2021 , Shinde 2021 ). In total, over 30,000 participants have 
been  immunized  with NVX -CoV2373  in clinical  trials  and 2,266,287  NVX -CoV2373  doses  have 
been administered in Australia, Canada, European Union (EU), Israel, Japan, New Zealand,  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  24  
 
Singapore,  South  Korea,  Switzerland,  Taiwan,  and the United  States  (US)  cumulatively  as of 17 
November 2022.  
Study  2019nCoV -302 was a Phase  3, randomized  (1:1),  observer -blinded,  placebo -controlled 
trial evaluating the efficacy, safety, and immunogenicity of 5 µg SARS -CoV -2 rS with  
50 µg Matrix -M adjuvant, administered 21 days apart on Days 0 and 21 as a coformulation, in 
15,139 healthy and medically stable (with comorbidities) participants 18 to 84 years of age 
conducted in the United Kingdom (UK). After the initial vaccination period, participants 
remained blinded and crossed over to the opposite treatment arm. An analysis of the primary 
efficacy endpoint, which included both immunogenicity and safety data, was performed. A total 
of 106 cases of polymerase chain reaction (PCR) -confirmed symptomatic mild, moderate, or 
severe COVID -19 were accrued for the final prespecified analysis of the primary endpoint, with 
10 (0.1%)  in the  NVX -CoV2373 group and 96 (1.4%)  in the  placebo group. All but 5 cases were 
mild or moderate in severity, with all 5 severe cases occurring in the placebo group. The  
resultant vaccine efficacy of NVX -CoV2373 to prevent symptomatic mild, moderate, or severe 
COVID -19 in baseline seronegative (to SARS -CoV -2) adult participants was 89.7% (95% CI: 
80.2, 94.6; p < 0.001), with a lower bound confidence interval (LBCI) > 30% meeting the 
prespecified study success criterion. PCR results of the final analysis by SARS -CoV -2 strain 
showed vaccine efficacy of 86.3% (95% CI: 71.3, 93.5) for the B.1.1.7 (Alpha) variant and 
96.4% (95% CI: 73.8, 99.5) for the ancestral (Wuhan) strain. NVX -CoV2373 induced robust 
immune responses (anti -S IgG and neutralizing antibody [Nab]), which were 1.3 -fold (anti -S 
IgG) and 1.4 -fold (Nab) higher in the younger age cohort (18 to 64 years) than in the older age 
cohort (65 to 84 years), but seroconversion rates (SCRs) were at least 98% in both age cohorts. 
NVX -CoV2373 was well tolerated, with similar frequencies of serious adverse events (SAEs), 
medically attended adverse events (MAAEs), and adverse events of special interest (AESIs) 
compared  to placebo.  Solicited  local  and systemic  reactogenicity  in a subset  of 2,714  participants 
were  higher  for NVX -CoV2373 than placebo, but the  majority of  reported events were classified 
as grade 1 following first vaccination and grade 1 or grade 2 following second vaccination. The 
most frequent local AEs following each vaccination were tenderness and pain, with relatively 
short median durations following first (≤ 2.0 days) and second (≤ 3.0 days) vaccination. The 
most frequent solicited systemic AEs following each vaccination were headache, fatigue, and 
muscle pain, with relatively short median durations following first (≤ 1.5 days) and second  
(≤ 2.0 days)  vaccination.  Across  the 2 age strata,  participants  in the older  age cohort  (65 to 
84 years of age) reported a lower frequency and intensity of solicited local and systemic  
treatment  emergent  adverse  events  (TEAEs)  than participants  in the younger  age cohort  (18 to 64 
years of age).  
Study  2019nCoV -301 is a Phase  3, randomized  (2:1),  observer -blinded,  placebo -controlled  trial 
with a pediatric expansion evaluating the efficacy, safety, and immunogenicity of NVX - 
CoV2373, administered 21 days apart on Days 0 and 21 as a coformulation, in 29,582 healthy 
and medically stable (with comorbidities or at high risk for COVID -19) adult participants  
18 years of age and older conducted in the United States (US) and Mexico and the safety and 
immunogenicity  of NVX -CoV2373  in 2,247  healthy  adolescent  participants  12 to < 18 years  of 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  25  
 
age conducted in the  US. In adults, final analysis of  the primary efficacy endpoint yielded a  VE 
of 90.41% (95% CI: 83.81, 94.32) for all participants. In addition, NVX -CoV2373 induced 
robust  immune  responses  and safety  data reflected  an acceptable  safety  profile.  These  data were 
submitted to the FDA in support of a request for Emergency Use Authorization. Subsequently, 
safety and immunogenicity data following a booster dose of NVX -CoV2373 from this study 
supported Emergency Use Authorization of the vaccine as a booster dose.  
The pediatric expansion of Study 2019nCoV -301 evaluated the efficacy, safety, and 
immunogenicity of NVX -CoV2373 in participants 12 to < 18 years of age. Out of the 1468 and 
730 participants in the NVX -CoV2373 and placebo groups, respectively, who received both 
vaccinations,  1277  (87.0%)  and 618 (84.7%),  respectively,  had at least 60 days of follow -up after 
their second  vaccination.  NVX -CoV2373  was well tolerated  and elicited  significantly  enhanced  - 
immune responses, with similar frequencies of SAEs, MAAEs, and AESIs compared to placebo. 
As of the data cut -off date for the primary efficacy analysis among 1,197 participants receiving  
2 doses of NVX -CoV2373 and 590 participants receiving 2 doses of placebo, a two -dose 
regimen of NVX -CoV2373 administered at least 21 days apart demonstrated high efficacy for 
preventing PCR -confirmed symptomatic mild, moderate, or severe COVID -19 (VE = 79.56% 
[95%  CI: 46.87,92.13]).  Of note,  efficacy  data were  collected  during  the time in which  the Delta 
variant of concern (VOC) was the predominant circulating variant in the US.  
As a continuation of the pediatric expansion of Study 2019nCoV -301, a third (booster) dose of 
NVX -CoV2373  was administered  in an open -label  manner  to participants  who remained  in study 
follow -up (either blinded or unblinded) and had received their full primary series of NVX - 
CoV2373  as planned.  Booster  doses  were  administered  no less than 5 months  after completion  of 
active vaccination. Immunogenicity and safety data following the booster dose demonstrated  
non-inferiority  of the booster  dose of NVX -CoV2373  vs the primary  series,  with a GMFR  of 
2.7 (95%  CI: 2.0, 3.5) and an LB of the 95% CI > 1.0 (primary  endpoint,  NAb  titers  vs the 
ancestral strain), and found the dose was well tolerated with an acceptable safety profile 
comparable with the primary series and similar data in adults.  
Study 2019nCoV -311 is an ongoing Phase 3, multi -part, randomized, observer -blinded trial in 
healthy adult participants who previously received prototype mRNA COVID -19 vaccines, with 
their last dose  of mRNA vaccine approximately 6 months prior  to study vaccination. In Part 1 of 
the study, 831 participants were randomized 1:1:1 to receive a single booster dose of either 
NVX -CoV2515,  NVX -CoV2373,  or a bivalent  vaccine  (NVX -CoV2515  + NVX -CoV2373,  5 μg 
total antigen). An interim analysis performed 28 days after study vaccination found the primary 
objective of the study was met, achieving the endpoints needed to demonstrate that the Omicron  
5 specific  vaccine  (NVX -CoV2515)  produced  a superior  antibody  response  to the Omicron  BA.1 
subvariant  when  compared  to the prototype  vaccine  (NVX -CoV2373)  at Day 14. Safety  analyses 
determined NVX -CoV2515, NVX -CoV2373, and the bivalent vaccine were all well -tolerated 
with comparable and acceptable safety profiles.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  26  
 
2.1.4 Benefit:  Risk  Assessment  
The SARS -CoV -2 rS nanoparticle vaccines contain purified protein antigens. They cannot 
replicate, the protein is not produced using infectious SARS -CoV -2, nor can the vaccines cause 
COVID -19. However,  in common  with all vaccines  produced  in cell culture  or other  systems,  the 
SARS -CoV -2 rS nanoparticle vaccines contain residual non -vaccine proteins derived from the 
production system, and sensitization to these, or the SARS -CoV -2 S protein itself, may 
theoretically occur. While the occurrence of anaphylaxis is possible with the administration of 
any vaccine,  whether  licensed  or in development,  no such reactions  have  been  observed  in any of 
the Sponsor’s  clinical  trials  to date.  As clinical  data become available,  with increased  exposure  it 
is possible that this profile may change. The risk of AEs related to hypersensitivity will be 
mitigated by observation of participants for at least 15 minutes after study vaccination.  
The risk for enhanced COVID -19 in immunized participants is a theoretical risk. There is 
currently  no evidence  for immunoenhancement  in nonclinical  testing  of SARS -CoV -2 rS or other 
Novavax baculovirus -Sf9-based vaccines taken into nonclinical evaluation or clinical trials.  
No risks have been identified in nonclinical or early clinical testing of SARS -CoV -2 or other 
coronavirus  vaccines (SARS -CoV  and MERS -CoV)  developed  using  the baculovirus -Sf9 system 
to date. In supportive toxicology studies with other viral GP nanoparticle vaccines developed 
using  the baculovirus -Sf9 system  with different  antigens,  findings  were  generally  consistent  with 
an immune response to the vaccine formulations. These toxicological investigations indicated 
that baculovirus -Sf9-produced antigens (up to 240 µg total nanoparticle dose) with Matrix -M 
adjuvant (up to 100 µg) were well tolerated in the animal and antigen system tested with no 
evidence of toxicity suggestive of any unusual risk or target organ for toxicity. Non -adverse 
findings, including local injection site inflammation and serum chemical markers of 
inflammation  (such  as C-reactive  protein),  were  transient  and considered  consistent  with immune 
system stimulation consequent to immunization.  
Myocarditis or pericarditis has been reported following vaccination with NVX -CoV2373 in 
clinical trials and following emergency use authorization, and it is possible that these reports 
represent  vaccine -associated  AEs similar  to those  associated  with messenger  ribonucleic  acid 
(mRNA) COVID -19 vaccines. While available data may not be sufficient to definitively 
establish a causal relationship with NVX -CoV2373, neither can a causal relationship be 
excluded.  
Myocarditis or pericarditis associated with mRNA vaccines has been reported in greatest 
numbers in males under the age of 30 years following a second dose, but cases have been 
reported in older males and in females as well, and also following the first dose. While some 
cases  required  intensive  care support,  available  data from  short -term follow -up suggest  that most 
individuals have had resolution of symptoms with conservative management. Information is not 
yet available about potential long -term-sequelae.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  27  
 
The Centers  for Disease  Control  and Prevention  (CDC)  has published  clinical  considerations  for 
myocarditis  and pericarditis  after receipt  of mRNA COVID -19 vaccines among  adolescents  and 
young adults which makes specific recommendations for the management of myocarditis and 
pericarditis ( CDC 2021 ). A surveillance and management plan for  suspected myocarditis and/or 
pericarditis cases based on CDC and American Heart Association (AHA) recommendations has 
been implemented in the clinical development plan of NVX -CoV2373 ( CDC 2021 , Law 2021 , 
Gargano 2021 ). 
Findings to date suggest that SARS -CoV -2 rS when administered with Matrix -M adjuvant 
(NVX -CoV2373)  demonstrated  an acceptable  safety  profile  and robust  immunogenicity  profile 
in healthy and medically stable adult participants 18 to 84 years. Results of an interim 35 -day 
reactogenicity analysis on 1,283 participants aged 18 to 84 years in Part 2 of  
Study 2019nCoV -101 and 2,714 participants 18 to 84 years in Study 2019nCoV -302 showed a 
similar reactogenicity profile between younger and older participants, with both local and 
systemic reactogenicity events occurring less frequently in older adults. In addition, nearly 
31,000 individuals have to date received at least 1 dose of NVX -CoV2373 and ongoing reviews 
of the accumulated  safety  data support  continued  development  of the vaccine  and vaccines  based 
on the same platform.  
For the NVX -CoV2373  vaccine,  clinical  efficacy  results  are also available  from  studies  run in 
the UK and South Africa. In the UK  study (Study 2019nCoV -302), the  overall efficacy of  the 
vaccine was 89.7% (95% CI: 80.2, 94.6) and, in post hoc analyses, efficacy estimates for the  
B.1.1.7  (Alpha)  variant  and for the ancestral  strain  were  86.3%  and 96.4%, respectively. In  the 
South  Africa  study  (Study  2019nCoV -501),  the efficacy  of the vaccine  in all study  participants 
was 48.6% (95% CI: 28.4, 63.1) and 55.4% (95% CI: 35.9, 68.9) in participants who were 
HIV-negative. The efficacy estimates in South Africa were generated in a period of > 90%  
B.1.351  (Beta)  variant  virus  circulation.  
2.2 Study  Rationale  
In response to the emergence of the Omicron variant of SARS -CoV -2, Novavax, in conjunction 
with SII, has developed a Matrix -M-adjuvanted rS protein nanoparticle vaccine using the 
sequenced genome from the Omicron XBB.1.5 subvariant (NVX -CoV2601) for the prevention 
of disease caused by SARS -CoV -2 using the same recombinant baculovirus and insect cell 
vaccine  platform  technology  employed  previously  to produce  other  SARS -CoV -2, influenza,  and 
respiratory syncytial virus vaccines. NVX -CoV2601 will also be used in combination with  
NVX -CoV2373  in the form  of a site-mixed  bivalent  vaccine  (NVX -CoV2373  + NVX -CoV2601) 
to explore the safety and immunogenicity of vaccines containing antigen for both the ancestral 
(Wuhan) and Omicron subvariant strain of SARS -CoV -2. 
In sera tested  from  vaccinees  who had received  prior  mRNA  vaccines,  Omicron  neutralization 
was completely lost in > 50% of individuals accompanied by a 43 -fold geometric mean titer 
(GMT) decrease for the Moderna vaccine and 122 -fold decrease for the Pfizer -BioNTech 
vaccine. In subjects who had been recently boosted, Omicron neutralization for the Moderna  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  28  
 
vaccine was only 6 -fold lower than for the original wild -type neutralization, similarly for the 
Pfizer -BioNTech vaccine, the fold decrease was only 4 ( Garcia -Beltran 2021 ). These tests show 
that 2 -doses of mRNA vaccines are effective against the wild -type variant, but suboptimal for 
inducing  equivalent  neutralizing  antibodies  to the Omicron  variant.  In participants  who had been 
boosted with an mRNA vaccine within the last 3 -months showed correlation in  
cross -neutralization  between  the wild-type variant and  the Omicron  variant.  
Novavax, Inc. is developing recombinant vaccines adjuvanted with the  saponin based Matrix -M 
adjuvant for the prevention of disease caused by SARS -CoV -2. Both nonclinical and clinical 
data to date support  continued  clinical  development  of SARS -CoV -2 rS vaccines  combined  with 
Matrix -M adjuvant as potential vaccines against SARS -CoV -2. 
This study is designed to assess the safety and immunogenicity of the Novavax Omicron 
XBB.1.5  subvariant  vaccine  (NVX -CoV2601)  alone  as a monovalent  product  or in combination 
with the prototype Novavax vaccine (NVX -CoV2373) as a bivalent product in adolescent 
participants  ≥ 12 to < 18 years  of age who previously  received  ≥ 2 doses  of approved/authorized 
monovalent and/or bivalent mRNA vaccines.  
If favorable  immunogenicity  and safety  profiles  are observed  following  the booster  doses  of the 
bivalent product (NVX -CoV2373 + NVX -CoV2601), this would support the use of variant 
and/or bivalent vaccines in the global COVID -19 vaccination effort.  
3 OBJECTIVES  AND  ENDPOINTS  
The primary objectives in this study are to assess the overall safety of 1 heterologous booster 
dose of NVX -CoV2601 and the bivalent vaccine (NVX -CoV2373 + NVX -CoV2601) and to 
describe  the NAb  responses  induced  against  the Omicron  XBB.1.5  strain.  An overview  of the 
study objectives and endpoints is provided in Table 2 . 
 
Table  2: Study  2019nCoV -314 Objectives  and Endpoints  
 
Tier Objectives  Endpoints  
Primary  Safety 
Objective and 
Endpoints  To assess  the overall  safety  of 1 
heterologous booster dose of  
NVX -CoV2601  and the bivalent  vaccine 
(NVX -CoV2373 + NVX -CoV2601).  • Incidence, duration, and severity of 
solicited  local  and systemic  AEs for 7 
days following vaccination.  
• Incidence,  severity,  and relationship  of 
unsolicited AEs through 28 days after 
vaccination  
• Incidence and severity of MAAEs 
attributed to study vaccine, AESIs 
(predefined list including PIMMCs, 
myocarditis and/or pericarditis, and 
complications  specific  to COVID -19), 
and SAEs through day 180 or EOS.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  29  
 
Table  2: Study  2019nCoV -314 Objectives  and Endpoints  
 
Tier Objectives  Endpoints  
Primary 
Immunogenicity 
Objective and 
Endpoints  To describe  the NAb  response  induced  by 
NVX -CoV2601 and the bivalent vaccine 
(NVX -CoV2373 + NVX -CoV2601)  
against  the Omicron  XBB.1.5  strain.  • NAb GMTs to the Omicron XBB.1.5 
strain,  assessed  at Day 28 following  initial 
study vaccination.  
• NAb  geometric  mean  fold rise (GMFR)  at 
Day 28 from baseline (Day 0).  
Secondary 
Objectives  To describe  the NAb  response  induced  by 
NVX -CoV2601 and the bivalent vaccine 
(NVX -CoV2373 + NVX -CoV2601)  
against  the Omicron  XBB.1.5  strain  over 
time.  • NAb GMTs to the Omicron XBB.1.5 
strain  at relevant  time points  (Days  0, 90, 
and 180).  
• NAb  GMFR  at relevant  time points  (Days 
90 and 180) from baseline (Day 0)  
To describe  immunoglobulin  G (IgG) 
antibody levels induced by  
NVX -CoV2601  and the bivalent  vaccine 
(NVX -CoV2373 + NVX -CoV2601)  
against  the Omicron  XBB.1.5  strain  over 
time.  • IgG GMEUs to the Omicron XBB.1.5 S 
protein at relevant time points (Days 0, 
90, and 180). Derived/calculated 
endpoints  based  on these  data will include 
GMFR.  
Exploratory  To describe the NAb and IgG antibody 
responses  induced  by NVX -CoV2601  and 
the bivalent vaccine (NVX -CoV2373 + 
NVX -CoV2601) against the ancestral 
(Wuhan) strain over time.  • NAb titers and IgG GMEUs to the 
ancestral  (Wuhan)  strain  at relevant  time 
points (Days 0, 90, and 180). 
Derived/calculated endpoints based on 
these data will include GMFR.  
To describe  antibody  responses  in a human 
angiotensin  converting  enzyme -2 (hACE2) 
receptor binding inhibition assay induced 
by NVX -CoV2601 and the bivalent 
vaccine (NVX -CoV2373 +  
NVX -CoV2601)  to the Omicron  XBB.1.5 
and ancestral (Wuhan) strains over time.  • GMTs to the Omicron XBB.1.5 and 
ancestral  (Wuhan)  strains  at relevant  time 
points (Days 0, 90, and 180). 
Derived/calculated endpoints based on 
these data will include GMFR.  
To describe antibody responses in a 
mucosal IgA -mediated hACE2 receptor 
binding inhibition assay induced by 
NVX -CoV2601  and the bivalent  vaccine  
(NVX -CoV2373  + NVX -CoV2601)  to the 
Omicron  XBB.1.5  and ancestral  (Wuhan) 
strains over time.  • GMTs to the Omicron XBB.1.5 and 
ancestral  (Wuhan)  strains  at relevant  time 
points (Days 0 and 28). 
Derived/calculated endpoints based on 
these data will include GMFR . 
To utilize  additional  assays  (current  or to 
be developed) to better characterize the 
immune response for future vaccine 
development needs.  • Additional  endpoints  to evaluate  immune 
responses  may be developed  based  on the 
assays used.  
To characterize  the severity  of COVID -19 
in participants who become infected 
during the course of the study.  • Detected  case will be characterized  as 
mild, moderate, or severe as assessed 
using the provided criteria.  
Abbreviations: AE = adverse event; AESI = adverse event(s) of special interest; ELISA = enzyme -linked 
immunosorbent assay; GMEU = geometric mean ELISA units; GMFR = geometric mean fold rise; GMT = 
geometric  mean  titer;  hACE2  = human  angiotensin -converting  enzyme  2; IgG = immunoglobulin  G; NAb  = 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  30  
 
neutralizing  antibody;  MAAE  = medically  attended  adverse  event;  NAb  = neutralizing  antibody;  PIMMC  = 
potentially immune -mediated medical condition; S = spike; SAE = serious adverse event; SARS -CoV -2 = 
severe acute respiratory syndrome coronavirus 2.  
 
 
4 STUDY  PLAN  
4.1.1 Study  Schematic  
 
Figure  1: Flow  Diagram  for Study  2019nCoV -314 
 
 
Abbreviations:  EOS  = end of study;  IM = intramuscular.  
Note:  Group  A = NVX -CoV2601  Day 0; Group  B = Bivalent  NVX -CoV2373  + NVX -CoV2601  Day 0. 
4.1.2 Study  Design  
This is a Phase  3, randomized,  observer  blinded  study  to evaluate  the safety  and immunogenicity 
of a booster dose of Omicron XBB.1.5 subvariant SARS -CoV -2 rS vaccines adjuvanted with 
Matrix -M adjuvant in previously vaccinated participants.  
Approximately  400 adolescents  who have  received  a regimen  of ≥ 2 doses  of the Moderna  and/or 
Pfizer -BioNTech monovalent and/or bivalent COVID -19 vaccines ≥ 90 days previously will be 
enrolled and randomized 1:1 to Group A or Group B.  
• Group  A: 1 dose of NVX -CoV2601  (1 on Day 0) 
• Group  B: 1 dose of bivalent  NVX -CoV2373  + NVX -CoV2601  (1 on Day 0) 
Participants  will remain  on study  for immunogenicity  and safety  data collection  through  
Day 180. A tabular  summary  of the study  design is  provided  below  in Table  3, and a complete 
outline of study procedures is provided in Section 6.1.2 . 

SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  31  
 
Table  3: Study  Groups  and Treatments  
 
Group  Previous  Vaccine  Novavax  Vaccine  Booster 
(antigen/adjuvant)  n 
A ≥ 2 doses  Moderna  
and/or 
Pfizer -BioNTech  NVX -CoV2601  (5 μg/50  μg) 200 
B Bivalent  NVX -CoV2373  + NVX -CoV2601  
(5 μg/50  μg [total])  200 
4.1.3 Design  Rationale  
This study is designed to assess the safety and immunogenicity of the Novavax Omicron 
XBB.1.5  subvariant  vaccine  (NVX -CoV2601)  alone  as a monovalent  product  or in combination 
with the prototype Novavax vaccine (NVX -CoV2373) as a bivalent product in adolescent 
participants  ≥ 12 to < 18 years  of age who previously  received  ≥ 2 doses  of approved/authorized 
monovalent and/or bivalent mRNA vaccines.  
Enrolled  participants  are intended  to match  a representative  US adolescent  population,  including 
participants with common vaccination histories and with no restrictions on prior COVID -19 
exposure. The sample size and study duration were selected to prioritize the collection of safety 
data. 
If favorable  immunogenicity  and safety  profiles  are observed  following  the booster  doses  of the 
bivalent product (NVX -CoV2373 + NVX -CoV2601), this would support the use of variant 
and/or bivalent vaccines in the global COVID -19 vaccination effort.  
5 POPULATION  
5.1 Recruitment  
Approximately 400 participants will be enrolled. Participants will be screened across 
approximately  25 different  study  sites located  in the US and Canada  (Canadian  sites contingent 
upon additional approval).  
Participants  will be medically  stable  male  and nonpregnant  females  ≥ 12 to < 18 years  of age 
who have  previously  received  ≥ 2 doses  of the Moderna  and/or  Pfizer -BioNTech  monovalent 
and/or bivalent vaccines ≥ 90 days prior to study vaccination.  
5.1.1 Definitions  
Participants  officially  enter  the Screening  Period  following  provision  of informed  consent.  
A screen  failure  is a consented  participant  who has been  deemed  ineligible  on the basis  of 1 or 
more eligibility criteria or who has withdrawn consent prior to treatment assignment.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  32  
 
An enrolled  participant  is one who has been  deemed  eligible  and has been  assigned  to a 
treatment group.  
5.1.2 Inclusion  Criteria  
To be included  in this study,  each individual  must  satisfy  all of the following criteria:  
1. Adolescents  ≥ 12 to < 18 years  of age  at screening  
2. Participant  and parent(s)/caregiver(s)  or legally  acceptable  representative  willing  and able 
to give informed consent and assent, as required, prior to study enrollment and to comply 
with study procedures.  
3. Participants of childbearing potential (defined as any participant who has experienced 
menarche  and who is NOT  surgically  sterile  [ie, hysterectomy,  bilateral  tubal  ligation,  or 
bilateral oophorectomy] or postmenopausal [defined as amenorrhea ≥ 12 consecutive 
months]) must agree to be heterosexually inactive from at least 28 days prior to 
enrollment and through the end of the study OR agree to consistently use a medically 
acceptable method of contraception listed below from ≥ 28 days prior to enrollment and 
through the end of the study.  
a. Condoms  (male  or female)  with spermicide (if  acceptable  in country)  
b. Diaphragm  with spermicide  
c. Cervical  cap with spermicide  
d. Intrauterine  device  
e. Oral or patch  contraceptives  
f. Norplant®, Depo -Provera®, or other  in country  regulatory  approved  contraceptive 
method that is designed to protect against pregnancy  
g. Abstinence,  as a form  of contraception,  is acceptable  if in line with the participant's 
lifestyle  
NOTE:  Periodic  abstinence  (eg, calendar,  ovulation,  sympto -thermal,  post-ovulation 
methods) and withdrawal are not acceptable methods of contraception.  
4. Is medically stable, as determined by the  investigator  (based on review  of health status, 
vital signs [to include body temperature], medical history, and targeted physical 
examination  [to include  body  weight]).  Vital  signs  must  be within  medically  acceptable 
ranges prior to the vaccination.  
5. Agrees  to not participate  in any other  SARS -CoV -2 prevention  or treatment  trials  for the 
duration of the study.  
NOTE:  For participants  who become  hospitalized  with COVID -19, participation  in 
investigational treatment studies is permitted.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  33  
 
6. Have  previously  received  ≥ 2 doses  of the Moderna  and/or  Pfizer -BioNTech  monovalent 
and/or bivalent COVID -19 vaccines with the last dose having been given ≥ 90 days 
previously prior to study vaccination.  
5.1.3 Exclusion  Criteria  
If an individual meets  any of the following  criteria, he  or she is ineligible  for this study:  
1. Received  COVID -19 vaccines  other  than Moderna  and/or  Pfizer -BioNTech  in the past, 
inclusive of clinical trial COVID -19 vaccines.  
2. Participation  in research  involving  receipt  of investigational  products 
(drug/biologic/device) within 90 days prior to study vaccination.  
3. Received  influenza  vaccination  within  14 days prior  to study  vaccination.  
4. Received any vaccine ≤ 45 days prior to study vaccination, except for rabies, human 
papilloma virus (HPV), tetanus -diphtheria (Td), tetanus, diphtheria, and pertussis 
(TDaP/DTap),  hepatitis  B virus  (HBV),  and meningococcal  vaccines  which  may be given 
as medically indicated.  
5. Any known  allergies  to products  contained  in the investigational  product.  
6. Any history  of anaphylaxis to  any prior  vaccine.  
7. Autoimmune  or immunodeficiency  disease/condition  (iatrogenic  or congenital)  requiring 
ongoing immunomodulatory therapy.  
NOTE:  Stable  endocrine  disorders  (eg, thyroiditis,  pancreatitis),  including  stable  diabetes 
mellitus with no history of diabetic ketoacidosis) are NOT excluded.  
8. Chronic administration (defined as > 14 continuous days) of immunosuppressant, 
systemic  glucocorticoids,  or other  immune -modifying  drugs  within  90 days prior  to study 
vaccination.  
NOTE:  An immunosuppressant  dose of glucocorticoid  is defined  as a systemic  dose 
≥ 10 mg of prednisone per day or equivalent. The use of topical or intranasal 
glucocorticoids  is permitted.  Topical  tacrolimus  and ocular  cyclosporin  are permitted.  
9. Received immunoglobulin, blood -derived products, or immunosuppressant drugs within 
90 days prior  to study  vaccination,  except  for rabies  immunoglobulin  which  may be given 
if medically indicated.  
10. Active  cancer  (malignancy)  on therapy  within  3 years  prior  to study  vaccination  (with  the 
exception of adequately treated non -melanomatous skin carcinoma or lentigo maligna 
and uterine  cervical  carcinoma  in situ without  evidence  of disease, at  the discretion  of the 
investigator).  
11. Participants  who are breastfeeding,  pregnant,  or who plan to become  pregnant  prior  to the 
end of study.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  34  
 
12. Suspected  or known  history  of alcohol  abuse  or drug addiction  within  2 years  prior  to the 
study vaccine dose that, in the opinion of the investigator, might interfere with protocol 
compliance.  
13. Any other  condition  that, in the opinion  of the investigator,  would  pose a health  risk to 
the participant if enrolled or could interfere with evaluation of the study vaccine or 
interpretation of study results (including neurologic or psychiatric conditions likely to 
impair the quality of safety reporting).  
14. Study team member or immediate family member of any study team member (inclusive  
of Sponsor,  clinical  research  organization  [CRO],  and study  site personnel  involved  in the 
conduct or planning of the study).  
15. Participants  with a history  of myocarditis  or pericarditis.  
16. Respiratory  symptoms  in the past 3 days (ie, cough,  sore throat,  difficulty  breathing).  
17. Temperature  of > 38°C  within  24 hours  of planned  study  vaccination  (site measured  or 
participant  measured).  
18. Blood  pressure  of ≥ 160/100 mmHg.  
5.2 Other  Considerations  for Eligibility  Criteria  
Participants  meeting  any of the following  criteria  may have  planned  study  vaccination  deferred 
for a later date, but these criteria are not exclusionary for study enrolment.  
• Respiratory  symptoms  in the past 3 days (ie, cough,  sore throat,  difficulty  breathing). 
Participant may be vaccinated once all symptoms have been resolved for > 3 days. 
Out-of-window study vaccination is allowed for this reason (see NOTE).  
• Temperature  of > 38°C  within  24 hours  of planned  study  vaccination  (site measured  or 
participant measured). Participant may be vaccinated once the fever has resolved and 
there has not been any temperature measured as being > 38°C for > 3 days without  
anti-pyrectics.  Out-of-window  study  vaccination  is allowed  for this reason  (see NOTE).  
NOTE:  PCR  testing  for SARS -CoV -2 is likely  to be indicated  for either  of the above 
reasons or if COVID -19 is suspected based on other symptoms or for potential 
exposure to SARS -CoV -2 infection through close contacts or based on local 
epidemiology.  
• Any participant  who is otherwise  eligible  with a blood  pressure  of ≥ 160/100  mmHg  may 
be retested onsite several times over a 3 -hour interval to achieve a lower blood pressure. 
If the blood  pressure  remains  ≥ 160/100  mmHg,  study  vaccination  should  be deferred for 
a later date if, at that time, the participant’s baseline blood pressure is found to be  
< 160/100 mmHg.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  35  
 
• Participants  found  to be SARS -CoV -2 positive  during  the study  may be excluded  from 
some analyses as per the statistical analysis plan (SAP) but will not be excluded from 
participation in the study.  
6 STUDY  CONDUCT  
A complete  description  of study  procedures  for participants  is provided  in Section  6.1.2  and a 
SOE is provided in Table 1 . 
6.1 Study  Summary  
6.1.1 Scheduled  Study  Visits  
All participants  will follow  the same  treatment  and assessment  schedule  and will remain  on study 
for immunogenicity and safety data collection through Day 180, for a total study duration of up 
to 194 days (approximately 7 months).  
During the study, participants will have the option of remote (home) visits for Visits 2 (Day 28), 
4 (Day  90), Unscheduled (UNSCH)  and EOS  (Day  180).  These  home  visits  will be conducted  by 
Illingworth  Research Group  who will act as an extension  of the study  trial sites.  Illingworth  Staff 
will be trained in the study and oversight will be provided by the PI  they are assigned to support. 
Tasks conducted by the Illingworth Research team will include but not be limited to mobile 
research  nursing,  patient  concierge,  medical  photography  (if applicable)  and any clinical  research 
services/assessments  as documented  in the study  protocol  Schedule  of Events  and study  plans  for 
each visit conducted.  
6.1.1.1  Scheduled  Study  Visits  
Scheduled  study  visits will  occur  for Screening  and at Days  0, 28, 56,  90 118, 146,  and 180: 
• Screening  Period  (Days  -14 to 0). 
• Day 0: Randomization  and booster  administration.  
− Screening  and Day 0 procedures  can be conducted  on the same  day when feasible.  
• Day 28: Safety  and immunogenicity  follow -up for all participants.  
• Day 56: Phone  Visit  - Safety  follow -up for all participants.  
• Day 90: Safety  and immunogenicity  follow -up for all participants.  
• Day 118: Phone  Visit  - Safety  follow -up for  all participants.  
• Day 146: Phone  Visit  - Safety  follow -up for  all participants.  
• Day 180: EOS visit for all participants. EOS procedures will be conducted via site visit 
when  possible.  These  procedures  should  also be conducted  for all participants  upon  early 
termination.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  36  
 
On vaccination  Day 0, participants  will remain  in the clinic  or under  study  staff observation  for 
at least 15 minutes post -vaccination to be monitored for any immediate hypersensitivity and 
anaphylaxis reactions. Participants will utilize an electronic diary (eDiary) to record 
reactogenicity following vaccination. All participants will be asked to record reactogenicity on 
the day of vaccination  and for an additional  6 days after  vaccination.  Should  any reactogenicity 
event  extend  beyond  6 days after vaccination  (toxicity  grade  ≥ 1), then it will be recorded  using 
the Continuing Solicited AE form and followed to resolution per ICH guidelines for dataset 
capture. The toxicology grading scale implemented in the eDiary for the study is included in 
Appendix 2 . 
Qualitative PCR tests will be performed on all participants on study Day 0. Confirmed 
symptomatic  cases  of COVID -19 should  be recorded  as an AE, SAE,  or COVID -19 relevant 
AESI  as appropriate.  Positive  PCR  swab  results  in asymptomatic  participants  should  also be 
entered as an AE.  
6.1.1.2  Unscheduled  Study  Visits  
Unscheduled Visits may be conducted throughout the duration of the study either via in -person 
or by a Home Health Care provider as deemed necessary by the principal investigator. In many 
cases, they may be conducted by study personnel for safety follow -up for any participant 
experiencing a medical issue while on study. During an Unscheduled Visit, the principal 
investigator may elect to perform any of the assessments listed in the SOE ( Table 1 ) including 
blood  sample  collection,  physical  assessments,  or other  optional  testing  for clinical  evaluation  of 
an AE. In situations where the unscheduled visit is not due to respiratory/non -respiratory 
symptoms consistent with suspected COVID -19, the visit may be done as an in -person clinical 
site visit or as a telehealth visit. If an in -person visit is done for non -COVID related symptoms, 
vital signs, physical examinations, and other procedures as needed may be done as requested by 
the Investigator.  
Participants and their guardians will be instructed to monitor for respiratory/non -respiratory 
symptoms of COVID -19 during the study. In cases of suspected COVID -19 illness where the 
participant has not been evaluated at an offsite medical facility, they must contact the site within 
3 days of symptom  onset.  If possible,  the participant  should  have  an in-person  visit to help gather 
vital signs and do any necessary work up inclusive of physical examination. In cases where the 
participant has already been at an offsite facility, the site should endeavor to retrieve the visit 
notes. Only in situations where the participant cannot have an in -person visit should a telehealth 
visit be planned. Procedures for this visit are described in Section 6.1.2.8.2 , and follow -up to 
confirm  and assess  the severity  of the case of COVID -19 will be conducted  at the next scheduled 
study visit.  
6.1.1.3  COVID -19 Monitoring and  Assessment  of Severity  
At each scheduled  study visit,  participants  will be asked  to report any  PCR/rapid  test confirmed 
cases  of COVID -19 that occurred  since  last contact.  Additional  follow -up for any prior reported  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  37  
 
cases  of COVID -19 (ie, an unscheduled  telehealth  visit due to suspected  COVID -19) will be 
conducted as well.  
For all medically attended cases of COVID -19, an attempt will be made to obtain all medical 
records  relevant  to the COVID -19 healthcare  visit and subsequent  treatment  in order  to assess  the 
severity of each case using the criteria provided in Appendix 3 . Note, only the severity score 
should be recorded in the electronic case report form (eCRF).  
All PCR/rapid  test confirmed  symptomatic  cases  of COVID -19 should  also be recorded  as an 
AE, SAE, or COVID -19 relevant AESI as appropriate.  
Positive  PCR  swab  results  (performed  in all participants  at Day 0) in asymptomatic  participants 
should also be entered as an AE.  
6.1.2 Study  Procedures  
6.1.2.1  Screening  Period  
The following procedures will be performed within 14 days of study vaccination. The Screening 
visit and Day 0 visit may be combined,  if feasible, at  any given  study  site. Screening  information 
collected  as part of a standard -of-care protocol  prior  to informed  consent  form  (ICF)  signing  may 
be used if collected during the same healthcare visit.  
• Written  informed  consent  will be obtained  in conformance  with Section  10.3 of this 
protocol.  
• Review  of medical  history,  including  prior  and concomitant  medical  conditions,  recent  
vaccinations  (≤ 90 days), and  significant  surgical procedures.  
• Review  of COVID -19 vaccination  status,  including  number  of prior  vaccinations, 
vaccination type, and timing of most recent vaccination.  
• Inclusion and exclusion criteria review via participant discussion and medical history 
review consistent with Section 4.1.1 . Specific exclusions to study vaccination will be 
assessed  before  any vaccination.  Waivers  for enrolling  participants  with exclusions  will 
not be given.  
• Demographics,  including  age, year of birth,  sex, race,  ethnicity,  weight,  height,  and body 
mass index (BMI; derived).  
• Prior  and concomitant  medications,  including  recent  and current  medications  at the time 
of screening to be reviewed to ensure eligibility criteria are fulfilled (see details in 
Section 7.4). 
• Vital  sign measurements,  including  respiratory  rate, blood  pressure,  pulse  rate, pulse 
oximetry, and temperature (oral or via forehead/ear reader).  
• Baseline  electrocardiogram  (ECG)  
• Urine  pregnancy  test for participants  of childbearing  potential  only.  A positive  urine 
pregnancy test at Screening will result in screen failure.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  38  
 
• Physical  examination  to include  head,  eyes,  ears, nose,  and throat  (HEENT),  neck,  lungs, 
heart, cardiovascular, abdomen, and musculoskeletal system/extremities to allow for 
study vaccination.  
• Assessment  of SAEs,  starting  from  the time of informed consent.  
6.1.2.2  Day 0 – On-site Study Vaccination  
The Screening  and Day 0 Visits  may be combined  whenever  feasible.  If these  visits  are not 
combined, then the following procedures need to be performed and recorded for Day 0.  
Participant  eligibility  must  be confirmed  prior  to vaccination.  
Prior  to study  vaccination,  all participants  with confirmed  eligibility  will have  the following 
procedures performed:  
• Inclusion  and exclusion  criteria  review  via participant  discussion  and medical  history 
review  consistent  with Section  4.1.1 . Specific  exclusions  to study  vaccination  will be 
assessed before any study vaccination.  
• Prior  and concomitant  medications,  including  recent  and current  medications  to be 
reviewed to ensure eligibility criteria are fulfilled (see details in Section 7.4). 
• Vital sign measurements, including respiratory rate, blood pressure, pulse rate, pulse 
oximetry,  and temperature  (oral  or via forehead/ear  reader).  On study  vaccination  days, 
vital sign measurements will be collected once before study vaccination to ensure 
participant has no evidence of fever prior to study vaccination.  
• Urine pregnancy test for participants of childbearing potential only. A urine pregnancy 
test will be performed  prior  to study  vaccination.  A positive  urine  pregnancy  test at any 
time will result in the participant not receiving any further study vaccination.  
• Symptom -directed  (targeted)  physical  examination.  Physical  examination  must  be done 
prior to study vaccination.  
• Nasal  swab (anterior  nares)  collection  for SARS -CoV -2 PCR  testing  
• Oral swab  for SARS -CoV -2 mucosal  IgA-mediated  hACE2  receptor -binding  inhibition 
assay  
• Blood  sampling  for immunogenicity  tests:  
− SARS -CoV -2 (ELISA  for anti-S-protein  serology).  
− SARS -CoV -2 serostatus  (anti-N-protein  serology).  
− SARS -CoV -2 NAb  assay.  
− Human  angiotensin  converting  enzyme -2 (hACE2)  receptor -binding  inhibition  assay.  
• Randomization/Enrollment  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  39  
 
At the time of study  vaccination,  the following  procedures  will be conducted  for all randomized 
participants:  
• Alcohol  swab  cleansing  of the injection  sites for study  vaccine administration  
• Vaccination  with study  vaccine  as an intramuscular  (IM)  injection.  
• Monitoring  for any immediate  hypersensitivity  and anaphylaxis  reactions.  Participants 
will remain in clinic for at least 15 minutes post -vaccination for safety monitoring.  
• Assessment  of unsolicited  AEs,  MAAEs  (all and related  to study  vaccination),  any SAEs, 
and AESIs (including PIMMCs, myocarditis and/or pericarditis, and complications 
specific to COVID -19). 
Following vaccination, participants will be  trained to utilize  an eDiary to record reactogenicity. 
All participants will be asked to record reactogenicity on the day of vaccination and for an 
additional 6 days after vaccination. Study site personnel should regularly review the eDiary for 
completeness.  Should  any reactogenicity  event  extend  beyond  6 days after vaccination  (toxicity 
grade ≥ 1), then it will be recorded using the Continuing Solicited AE form and followed to 
resolution  per ICH  guidelines  for dataset capture. The  toxicology  grading  scale  implemented  in 
the eDiary for the study is included in Appendix 2 . 
6.1.2.3  Day 28 – In-person/Home  Health  Care  Follow -up Visit  (-1 to + 7 Days)  
All participants  will have  the following  procedures  performed  on Day  28: 
• Prior  and concomitant  medications  (see details  in Section  7.4). 
• Oral swab  for SARS -CoV -2 mucosal  IgA-mediated  hACE2  receptor -binding  inhibition 
assay.  
• Blood  sampling  for immunogenicity  tests:  
− SARS -CoV -2 (ELISA  for anti-S-protein  serology).  
− SARS -CoV -2 serostatus  (anti-N-protein  serology).  
− SARS -CoV -2 NAb  assay.  
− hACE2  receptor -binding  inhibition  assay.  
• COVID -19 monitoring  and assessment  of severity.  
• Assessment  of unsolicited  AEs,  MAAEs  (all and related  to study  vaccination),  any SAEs, 
and AESIs (including PIMMCs, myocarditis and/or pericarditis, and complications 
specific to COVID -19). 
6.1.2.4  Day 56 – Phone  Follow -up Visit  (± 7 Days)  
All participants  will have  the following  safety  information  collected  via a remote  visit (eg, phone 
call) on Day 56:  
• Prior  and concomitant  medications  (see details  in Section  7.4). 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  40  
 
• COVID -19 monitoring  and assessment  of severity  
• Assessment  of any SAEs,  AESIs  (including  PIMMCs,  myocarditis  and/or  pericarditis, 
and complications specific to COVID -19), and related MAAEs.  
6.1.2.5  Day 90 – In-person/Home  Health  Care  Follow -up Visit  (± 7 Days)  
All participants  will have  the following  procedures  performed  on Day  90: 
• Prior  and concomitant  medications  (see details  in Section  7.4). 
• Symptom -directed  (targeted)  physical  examination.  
• Blood  sampling  for immunogenicity  tests:  
− SARS -CoV -2 (ELISA  for anti-S-protein  serology).  
− SARS -CoV -2 serostatus  (anti-N-protein  serology).  
− SARS -CoV -2 NAb  assay.  
− hACE2  receptor -binding  inhibition  assay.  
• COVID -19 monitoring  and assessment  of severity  
• Assessment  of any SAEs,  AESIs  (including  PIMMCs,  myocarditis  and/or  pericarditis, 
and complications specific to COVID -19), and related MAAEs.  
6.1.2.6  Day 118 – Phone  Follow -up Visit  (± 7 Days)  
All participants  will have  the following  safety  information  collected  via a remote  visit (eg, phone 
call) on Day 56:  
• Prior  and concomitant  medications  (see details  in Section  7.4). 
• COVID -19 monitoring  and assessment  of severity  
• Assessment  of any SAEs,  AESIs  (including  PIMMCs,  myocarditis  and/or  pericarditis, 
and complications specific to COVID -19), and related MAAEs.  
6.1.2.7  Day 146 – Phone  Follow -up Visit  (± 15 Days)  
All participants  will have  the following  safety  information  collected  via a remote  visit (eg, phone 
call) on Day 146:  
• Prior  and concomitant  medications  (see details  in Section  7.4). 
• COVID -19 monitoring  and assessment  of severity  
• Assessment  of any SAEs,  AESIs  (including  PIMMCs,  myocarditis  and/or  pericarditis, 
and complications specific to COVID -19), and related MAAEs.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  41  
 
6.1.2.8  Unscheduled  Visit  
6.1.2.8.1  General  Unscheduled  Visit  
General Unscheduled Visits not due to respiratory/non -respiratory symptoms suspected to be 
COVID -19 will be conducted by study personnel for safety follow -up for any participant 
experiencing  a general  medical  issue  while  on study.  During  this visit,  the principal  investigator 
may also perform any of the assessments listed in the SOE ( Table 1 ) including blood sample 
collection,  physical  assessments,  or other  optional  testing  if needed  for the clinical  evaluation  of 
an AE.  
• Prior  and concomitant  medications  (see details  in Section  7.4). 
• Vital  sign measurements,  including  respiratory  rate, blood  pressure,  pulse  rate, pulse 
oximetry, and temperature (oral or via forehead/ear reader).  
• Full physical  examination.  
• Assessment  of unsolicited  AEs (only  for Unscheduled  Visits  occurring  through  28 days 
after last study vaccination), MAAEs (only related MAAEs should be recorded if more 
than 28 days after last vaccination),  SAEs,  and AESIs  (including  PIMMCs,  myocarditis 
and/or pericarditis, and complications specific to COVID -19). 
• Blood sample collection and other optional testing may be performed during an 
Unscheduled  Visit  if directed  by the Investigator  for clinical  evaluation  of an AE. 
6.1.2.8.2  Unscheduled  Visit  Due to Suspected  COVID -19 
In cases  of suspected  COVID -19 illness  where  the participant  has not been  evaluated  at an offsite 
medical facility, they must contact the site within 3 days of symptom onset. If possible, the 
participant  should  have  an in-person  visit to help gather  vital signs  and do any necessary  work  up 
inclusive of physical examination. In cases where the participant has already been at an offsite 
facility, the site should endeavor to retrieve the visit notes. Only in situations where the 
participant cannot have an in -person visit should a telehealth visit be planned.  
For all telehealth  visits:  
• Prior  and concomitant  medications  (see details  in Section  7.4). 
• Nasal  swab (anterior  nares)  collection  for SARS -CoV -2 PCR  testing  
• Assessment  of unsolicited  AEs (only  for Unscheduled  Visits  occurring  through  28 days 
after last study vaccination), MAAEs (only related MAAEs should be recorded if more 
than 28 days after last vaccination),  SAEs,  and AESIs  (including  PIMMCs,  myocarditis 
and/or pericarditis, and complications specific to COVID -19). 
6.1.2.9  Day 180 – End of Study  In-person/Home  Health  Care  Visit  (± 15 Days)  
All participants  will have  the following  procedures  performed  on End  of Study/In -Person  Home  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  42  
 
Health  Care  Visit.  
• Prior  and concomitant  medications  (see definitions  in Section  7.4). 
• Vital  sign measurements,  including  respiratory  rate, blood  pressure,  pulse  rate, pulse 
oximetry, and temperature (oral or via forehead/ear reader).  
• Symptom -directed  (targeted)  physical  examination.  
• Blood  sampling  for immunogenicity  tests:  
− SARS -CoV -2 (ELISA  for anti-S-protein  serology).  
− SARS -CoV -2 serostatus  (anti-N-protein  serology).  
− SARS -CoV -2 NAb  assay.  
− hACE2  receptor -binding  inhibition  assay.  
• COVID -19 monitoring  and assessment  of severity  
• Assessment  of SAEs,  AESIs  (including  PIMMCs,  myocarditis  and/or  pericarditis,  and 
complications specific to COVID -19), and related MAAEs.  
• Completion  of the EOS form.  
6.2 Immunogenicity  Assessments  
Blood  samples  will be taken  at the time points  specified  in the procedures  above  and in the SOEs 
(Section  1.1) to assess  immune  response  (eg, IgG  ELISA  for anti-S protein serology,  NAb  assay, 
and hACE2 receptor -binding inhibition assay).  
Oral swabs  will be taken  at the time points  specified  in the procedures  above  and in the SOEs 
(Section 1.1) to assess IgA mediated hACE2 receptor -binding inhibition.  
hACE2 levels will be obtained at Day 0 and Day 28 from saliva biofluid samples to provide 
information  about  the mucosal  IgA-mediated  antibody  response  to SARS -CoV -2. The salivary 
gland epithelial cells express hACE2 and harbor a significant population of IgA -producing 
plasma cells. Secretory IgA in the saliva has been shown to have potent neutralizing activity 
against SARS -CoV -2 (Sheikh -Mohammed 2022).  
The details  on the handling,  processing,  and shipping  of immunogenicity  samples  will be 
provided separately in a laboratory manual.  
Participants will be asked to provide consent for the use of samples for future testing for assay 
development  related  to SARS -CoV -2 or other  pathogens.  Aliquots  of all collected  samples  from 
this study may be retained for the stated purposes for a maximum of 25 years (starting from the 
date at which the last participant had the last study visit), unless local rules, regulations, or 
guidelines require different time frames or different procedures, in accordance with participant 
consent.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  43  
 
6.3 Discontinuation  or Withdrawal  
6.3.1 Individual Participants  
6.3.1.1  Withdrawal  from  Study  
Participants  are free to withdraw  from  the study  at any time upon  request.  Participation  in the 
study may be stopped at any time at the discretion of the investigator or at the request of the 
Sponsor.  
Participants  may refuse  further  procedures  (including  study  vaccination)  but are encouraged  to 
remain in the study for safety follow -up. In such cases where only safety is being conducted, 
participant  contact  could  be managed  via telemedicine  contact  (eg, telephone,  web chat,  video, 
FaceTime).  
Any participant  who withdraws  from  the study  prematurely  will undergo  all EOS  assessments  at 
the time of withdrawal. The reason for the early EOS visit must be entered as withdrawal from 
study on the EOS form.  
Vaccination  with a non-study,  approved  or deployed  SARS -CoV -2 vaccine  alone  will not be 
considered a reason for withdrawal from the study.  
6.3.1.2  Replacement  of Participants  
Participants who sign the ICF but withdraw, are withdrawn or terminated from this study, or are 
lost to follow up prior to study vaccination may be replaced. Participants who receive study 
vaccine  and subsequently  withdraw,  are discontinued  from  additional  study  visits,  are terminated 
from the study, or are lost to follow -up will not be replaced.  
6.3.1.3  Participants  Lost  to Follow -up 
Whenever  possible,  any participant  who withdraws  from  the study  prematurely  will undergo  all 
EOS  assessments.  Any participant  who fails to return  for final assessments  will be contacted  by 
the site in an attempt to have them comply with the protocol.  
All reasonable efforts, including contact of emergency contact, must be made to locate 
participants to determine and report their ongoing status. Lost to follow -up is defined by the 
inability to reach the participant after a minimum of 3 documented phone calls, text messages, 
faxes  or emails  (not performed  on the same  day), as  well as a lack of response  by the participant 
to one registered mail letter. All attempts should be documented in the participant’s source 
documents  and/or  medical  records.  If it is determined  that the participant  has died,  the study  site 
will use permissible local methods to obtain the date and cause of death and as much other 
information as can be obtained, including post -mortem reports.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  44  
 
The status of  participants who fail to complete  final assessments will be  documented in the 
eCRF.  Data  that would  have  been  collected  at subsequent  visits  will be considered  missing.  
6.3.1.4  Study  Vaccination  Pause  Rules  
Study vaccination will be paused in the event of reports of 2 or more events of probable or 
confirmed  pericarditis  or myocarditis  (Table  5), pending  review  of cases  by the Central  Cardiac 
Adjudication Committee that will report the results of their adjudication to the Sponsor to 
determine whether enrollment may be resumed.  
Adverse events meeting any one of the following criteria will result in a hold being placed on 
subsequent  vaccinations  pending  further  review  by the Sponsor’s  Safety  Monitoring  Committee 
(SMC):  
• One or more  participant  with an SAE  considered  related  to the investigational  vaccine  by 
the investigator and by the Sponsor.  
• Three  or more  participants  with grade  3 (severe)  single  AE preferred  term considered 
related to the investigational vaccine by the investigator and by the Sponsor.  
In addition, any SAE assessed as related to vaccine (by study investigator and/or the Sponsor) 
will be reported to the Sponsor’s SMC Chair as soon as possible, and within 24 hours of the 
Sponsor’s awareness of the event. If a pause rule is met, the SMC will conduct a safety review 
within 48 hours of the identification of AEs meeting the pause rule definition. In addition, the 
SMC  Chair  will advise  the Clinical  Team  to advise  all sites to immediately  pause  enrolment  and 
further dosing the study participants. An ad hoc Sponsor’s SMC meeting will be convened to 
review the data and make alternative recommendations. The Sponsor’s SMC Charter defines 
processes for how this review will occur and how the Chair’s recommendations will be 
documented.  
The Sponsor,  along  with medical  monitor  (Syneos),  may request  an SMC  review  for any safety 
concerns deemed clinically significant that may arise in the trial and not associated with any 
specific pause rule.  
6.4 Study  Termination  
Although  the Sponsor  has every  intention  of completing  the study,  they reserve  the right  to 
discontinue it at any time for clinical or administrative reasons.  
The EOS is defined as the date on which the last participant completes the last study visit 
(including the EOS visit and any additional long -term follow -up). Any additional long -term 
follow -up that is required  for monitoring  of the resolution  of an AE or finding  may be appended 
to the clinical study report.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  45  
 
7 STUDY  INTERVENTIONS  
Study  vaccinations  will comprise  1 IM injection  with the study  treatment  assigned  (Table  4). 
 
Table  4: Investigational  Treatments  Used  in This  Study  
 
Product  Section  Antigen  Dose  Route  Manufacturer  
NVX -CoV2601 coformulated Omicron XBB.1.5 
SARS -CoV -2 rS vaccine  with Matrix -M adjuvant  7.1.1  5 μg IM Serum  Institute 
of India  
Prototype/XBB.1.5  Bivalent  Vaccine  
(Site -mixed  NVX -CoV2373  + NVX -CoV2601)  
coformulated  with Matrix -M adjuvant   
7.1.2   
5 μg (total)   
IM Serum  Institute 
of India  
Abbreviations:  IM = intramuscular  
7.1 Description  of Products  
7.1.1 NVX -CoV2601  (5 µg) 
7.1.1.1  Formulation,  Storage,  Preparation,  and Handling  
NVX -CoV2601 (5 µg): Coformulated Omicron XBB.1.5 SARS -CoV -2 rS vaccine with Matrix - 
M adjuvant: supplied as a solution for preparation for injection, at a concentration of 10 µg 
antigen  and 100 µg adjuvant  per mL. All study  vaccines  must  be stored  according  to the labelled 
instructions in a secure cabinet or room with access restricted to necessary clinic personnel. The 
study site will be required to keep a temperature log to establish a record of compliance with 
storage conditions.  
The NVX -CoV2601  vaccine  with Matrix -M adjuvant  should  be stored  at 2°C to 8°C in a secured  
location.  DO NOT  FREEZE.  
7.1.1.2  Dosing  and Administration  
The vaccine  should  be drawn  into a syringe  on the day of administration  by a qualified  member 
of study site personnel and should be administered according to standard practice by qualified 
study site personnel as directed in the Pharmacy Manual.  
All injections  will be administered  in a 0.5 mL injection  volume  at a dose of 5 µg antigen  with 
50 µg Matrix -M adjuvant at each injection.  
7.1.2 Prototype/XBB.1.5  Bivalent  Vaccine  (5 µg [Total])  
7.1.2.1  Formulation,  Storage,  Preparation,  and Handling  
The bivalent  vaccine  containing  antigen  for the ancestral  (Wuhan)  SARS -CoV -2 strain  and 
Omicron  XBB.1.5  subvariant,  will be prepared  from  study  supplies  of NVX -CoV2373  and 
NVX -CoV2601.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  46  
 
All study vaccines must be stored according to the labelled instructions in a secure cabinet or 
room  with access  restricted  to necessary  clinic  personnel.  The study  site will be required  to keep 
a temperature log to establish a record of compliance with storage conditions.  
The vials  for the preparation  of the bivalent vaccine  with Matrix -M adjuvant should  be stored at 
2°C to 8°C in a secured  location.  DO NOT  FREEZE.  
On the day of administration, the bivalent vaccine should be mixed according to the Pharmacy 
Manual in the clinic pharmacy or in an area designated for this function. All vaccines which are 
diluted  or mixed  in the study  site clinic/investigational  pharmacy  should  be used within  1 hour of 
being prepared and drawn into a syringe. For additional preparation, storage, and handling 
information for the bivalent vaccine, refer to the provided Pharmacy Manual.  
7.1.2.2  Dosing  and Administration  
The bivalent vaccine should be prepared and drawn into a syringe on the day of administration 
by a qualified  member  of study  site personnel  and should  be administered  according  to standard 
practice by qualified study site personnel as directed in the Pharmacy Manual.  
All injections will be administered in a 0.5 mL injection volume at a dose of 5 µg total antigen 
(2.5 µg prototype  antigen  + 2.5 µg Omicron  XBB.1.5  antigen)  with 50 µg Matrix -M adjuvant  at 
each injection.  
7.2 Treatment  Assignment  and Bias Minimization  
7.2.1 Treatment  Allocation  
An Interactive Web Response System (IWRS) will be responsible for the allocation of 
randomization  numbers  to individual  participants.  A copy  of the randomization/enrollment  code 
with true treatment allocations will be held by Syneos during the study. A separate open -label 
serialized list (containing carton/vial treatments) will be provided to clinical supplies for 
investigational medical product (IMP) packaging and labeling.  
7.2.2 Randomization  Strategy  and Procedure  
Randomization  will take place  on Day 0 after confirmation  that the participant  meets  the 
inclusion/exclusion criteria.  
Eligible participants will be randomized 1:1 to Group A or Group B (approximately 200 
participants  each).  Randomization  will be stratified  by number  of prior  mRNA  COVID -19 
vaccinations received and site.  
Within each study site, participants will be randomized to study treatment according to a list 
produced  by Syneos.  Prior  to production,  the randomization  specification  will be reviewed  and 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  47  
 
agreed  to by the study  team  (the Sponsor  and Syneos).  Block  size is considered  potentially 
unblinding information and will only be known by unblinded study personnel.  
7.2.3 Extent  and Maintenance  of Blinding  
This is a double -blind study. To maintain the blind, predetermined unblinded study site 
personnel  will manage  vaccine  logistics,  preparation,  and potentially  administration  according  to 
the Pharmacy Manual so as to maintain the blind from the remainder of the study site personnel 
and participants.  The unblinded  study  site personnel  may administer  study  vaccine  if qualified  to 
do so but will not be involved in study related assessments or have participant contact for data 
collection after administration of study vaccine.  
7.2.4 Unblinding Procedures  
7.2.4.1  Planned Unblinding  
A participant’s  vaccine  assignment  will not be revealed  to the site study  team  until the end of the 
study. Participants will be informed about which product they received as soon as feasible after 
the end of the study.  
7.2.4.2  Unplanned  or Unintentional  Unblinding  
A participant’s vaccine assignment will not be revealed to the site study team until the end of the 
study unless medical treatment of the participant depends on knowing the study vaccine the 
participant  received.  Should  a situation  arise  where  unblinding  is required,  the investigator  at that 
study site has the sole authority to obtain immediate unblinding via the IWRS. Prior to 
unblinding, or as soon thereafter as possible, the investigator should contact the Syneos Medical 
Monitor to discuss the medical emergency and the reason for revealing the actual vaccine 
combination received by that participant. Emergency code breaks performed using the IWRS 
must be clearly explained and justified in the eCRF. The date on which the code was broken  
must also be documented.  
When  the investigator contacts  the IWRS  system  to break  a treatment  code for  a participant,  they 
must  provide  the requested  participant  identifying  information  and confirm  the necessity  to break 
the treatment code for the participant. The investigator will then receive details of the study 
treatment for the specified participant and a blinded confirmation to document the unblinding 
will generate. The system will automatically inform the Sponsor and the Syneos Clinical Team 
via email that the code has been broken, but no treatment assignment will be communicated.  
It is the investigator’s  responsibility  to ensure  that there  is a procedure  in place  to allow  access  to 
the IWRS in case  of emergency. The  investigator will inform the  participant how  to contact their 
backup in cases of emergency when they are unavailable. The investigator will provide the 
protocol number, study vaccine name if available, participant number, and instructions for 
contacting the local entity which has responsibility for emergency code breaks to the participant  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  48  
 
in case an emergency  treatment  code  break  is required  at a time when  the investigator  and 
backup are unavailable.  
7.3 Assessment  and Verification  of Compliance  
All doses of the study vaccine should be administered in the clinical unit under direct 
observation  of clinic  personnel  and recorded  in the eCRF.  Clinic  personnel  will confirm  that the 
participant has received the entire dose.  
The location  (right  or left arm, or other  location  if required),  date,  and timing  of all doses  of 
study  vaccine  will be recorded  in the participants’  eCRF.  If a participant  is not administered 
study vaccine, the reason for the missed dose will be recorded.  
7.4 Prior  and Concomitant  Therapies  
Administration of medications, therapies, or vaccines will be recorded in the eCRF. Prior 
medications include recent (≤ 90 days) and current medications and non -COVID -19 
vaccinations. Concomitant medications will include all medications (including vaccines) taken 
by the participant  Day 0 through  EOS  (or through the  early  termination  visit if prior  to that time). 
Prescription  and over-the-counter  (OTC)  drugs  will be included.  Do not record  herbals,  vitamins, 
and supplements.  
Receipt  of any approved  or authorized  COVID -19 vaccine  should  also be recorded  through  EOS. 
Site staff will record the date(s) and brand of the approved or authorized SARS -CoV -2 vaccine 
combination received.  
7.4.1 Prohibited  Therapies  
The following  therapies  are prohibited  within  the specified  timeframes  of study  conduct  except 
to the extent that they are required to treat an ongoing illness or to maintain the participants’ 
health:  
• No COVID -19 vaccines  during  the course  of the study.  
• No other vaccines (except for a licensed seasonal influenza vaccine as described in the 
next bullet or rabies, HPV, Td, TDaP, DTap, HBV, and meningococcal vaccines [if 
medically  indicated])  will be allowed  within  45 days prior  to study  vaccination  or until 28 
days after study vaccination.  
• No influenza  vaccine  will be allowed  within  14 days prior  to study  vaccination  and 
within 14 days after study vaccination.  
• No investigational  product  (drug/biologic/device)  within  90 days prior  to study 
vaccination until after the last study visit.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  49  
 
• No chronic  administration  (defined  as > 14 continuous  days)  of any immunosuppressant 
medication within 90 days prior to study vaccination until the last study visit (except 
topical or intranasal steroids, or short -term oral steroids with course lasting ≤ 14 days). 
Topical tacrolimus and ocular cyclosporine are permitted. Rabies immune globulin 
should be administered if medically indicated.  
8 SAFETY  MONITORING  
The timing  and frequency  of all safety  assessments  are listed  in the SOE  (Section  1.1). 
Solicited and unsolicited AEs will be graded for severity using the provided criteria  
(Appendix  2). Recording  of solicited  and unsolicited  AEs will be conducted  by electronic  data 
capture  (EDC).  AESIs,  including  PIMMCs,  myocarditis  and/or  pericarditis,  and complications 
specific to COVID -19, will also be monitored (see Appendix 1  for details).  
A Central Cardiac Adjudication Committee has been established to adjudicate suspected 
myocarditis  and/or  pericarditis  cases  in the clinical  development  plan of NVX -CoV2373. 
Outcomes  of the adjudications  will be communicated  to the Sponsor’s  Safety  Monitoring 
Committee (SMC).  
8.1 Definitions  
• Adverse event – An AE is any untoward medical occurrence associated with the use of 
an intervention in humans whether or not it is considered intervention -related. Any 
abnormal laboratory test results or other safety assessments (eg, physical examination, 
vital signs measurements) that are clinically significant in the medical and scientific 
judgment  of the investigator  (ie, not related  to progression  of underlying  disease)  will be 
considered AEs. An exacerbation of a chronic or intermittent pre -existing condition, 
including either an increase in frequency and/or intensity, will be considered an AE.  
• Serious  adverse  event  (SAE)  – An event  is considered  “serious”  if, in the view  of either 
the Investigator or Sponsor, it results in any of the following outcomes:  
− Death  
− A life -threatening AE (an event is considered “life -threatening” if, in the view of 
either the investigator or Sponsor, its occurrence places the patient or participant at 
immediate  risk of death.  It does not include  an AE or suspected  adverse  reaction  (AR) 
that, had it occurred in a more severe form, might have caused death.)  
− Inpatient hospitalization or prolongation of existing hospitalization. In general, 
hospitalization signifies that the participant has been detained, usually involving an 
overnight stay, at the hospital or emergency ward for observation and/or treatment 
that would not have been appropriate in the physician’s office or outpatient setting. 
Hospitalization  for elective  treatment  of a pre-existing  condition  that did not worsen 
from baseline is not considered an SAE.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  50  
 
− A persistent  or significant  incapacity  or substantial  disruption  of the ability  to conduct 
normal life functions  
− A congenital  anomaly/birth  defect  
− Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the patient or participant and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition. 
Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room (ER) or at home, blood dyscrasias or convulsions 
that do not result  in inpatient  hospitalization,  or the development  of drug dependency 
or drug abuse.  
• Causality or relatedness – For each AE/SAE, the investigator must document in the 
medical  notes  that they have  reviewed  the AE/SAE  and have  provided  an assessment  of 
causality as follows.  
− Not Related:  There  is no reasonable  possibility  of relationship  to study  vaccine.  The 
AE does not follow a reasonable temporal sequence from administration of study 
vaccine or can be reasonably explained by the participant’s clinical state or other 
factors (eg, concurrent diseases, and concomitant medications).  
− Related: There is a reasonable possibility of relationship to study vaccine. The AE 
follows a reasonable temporal sequence from administration of study vaccine and 
cannot be reasonably explained by the participant’s clinical state or other factors (eg, 
concurrent diseases or concomitant medications), represents a known reaction to 
study vaccine or other vaccines in its class, is consistent with the known 
pharmacological  properties  of the study  vaccine,  and/or  resolves  with discontinuation 
of the study vaccine (and/or recurs with re -challenge, if applicable).  
• Adverse  reaction (AR) – An AR is any AE caused  by an IP. 
• Suspected  adverse  reaction  (SAR)  – An SAR  is any AE for which  there  is a reasonable 
possibility  that the IP caused  the AE. For the purposes  of investigational  new drug (IND) 
safety reporting, “reasonable possibility” means there is evidence to suggest a causal 
relationship between the IP and the AE. SAR implies a lesser degree of certainty about 
causality than AR.  
• Unexpected – An event is considered unexpected if it is not listed in the IB, is not listed 
at the specificity or severity that has been observed, or, if an IB is not required or 
available, is not consistent with the risk information described in the General 
Investigational Plan or elsewhere in the IND. Unexpected also refers to events that are 
mentioned in the IB as occurring with a class of IPs or as anticipated from the 
pharmacological  properties  of the IP but are not specifically  mentioned  as occurring  with 
the particular IP under investigation.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  51  
 
• Severity or intensity – The severity (or intensity) of an AE/SAE refers to the extent to 
which  it affects  the participant's  daily  activities  and will be classified  as mild,  moderate, 
or severe using the following criteria:  
− Mild:  These  events  require  minimal  or no treatment  and do not interfere  with the 
participant's daily activities.  
− Moderate: These events result in a low level of inconvenience or require minor 
therapeutic  measures.  Moderate  events  may cause  some  interference  with normal 
functioning.  
− Severe: These events interrupt a participant's usual daily activity and may require 
systemic  drug therapy  or other  treatment.  Severe  events  are usually  incapacitating.  
If the severity  of an AE/SAE  changes,  the most  intense  severity  should  be reported.  An 
AE/SAE characterized as intermittent does not require documentation of the onset and 
duration  of each episode.  Grading  criteria  for specific  AEs are provided  in Appendix  2. 
8.2 Documenting  Adverse  Events  
At every study visit, participants will be asked to report any medically related changes in their 
well-being.  They  will also be asked  if they have  been  hospitalized,  had any accidents,  used any 
new medications, or changed concomitant medication regimens (both prescription and OTC 
medications).  
In addition  to participant  observations,  AEs will be documented  from  any data collected  on the 
AE page of the eCRF or other documents that are relevant to participant safety.  
Care  will be taken  not to introduce  bias when  detecting  AEs,  MAAEs,  and SAEs.  Open  ended 
and non-leading  verbal  questioning  of the participant  is the preferred  method  to enquire  about 
AE occurrences. AESIs will be inquired about according to the specific diseases listed in 
Appendix 1 . 
When an AE/SAE occurs, it is the responsibility of the investigator to review all available 
documentation  (eg, hospital  progress  notes,  laboratory  reports,  and diagnostics  reports)  related  to 
the event. The investigator will then record all relevant AE/SAE information in the eCRF.  
It is not acceptable for the investigator to send photocopies of the participant’s medical records 
in lieu of completion of the AE/SAE eCRF page. There may be instances when copies of 
medical records for certain cases are requested. In this case, all participant identifiers, with the 
exception  of the participant  number,  will be redacted  on the copies  of the medical  records  before 
submission. The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  52  
 
The following  variables  will be recorded  for each AE: verbatim/AE  description  and date for AE 
start and stop, severity, seriousness, causality, any other action taken, and the outcome. A new 
AE must be recorded if the severity of the AE changes.  
Should  an SAE  have  an outcome  of death,  the report  should  contain  a comment  regarding  the 
co-involvement of progression of disease, if appropriate, and should assign main and 
contributory causes of death.  
8.2.1 Details  of the Adverse Event  
8.2.1.1  Assessment  of Causality  
There may be situations in which an SAE has occurred, and the investigator has minimal 
information to include in the initial report. However, it is very important that the investigator 
always  makes  an assessment  of causality  for every  event  before  the initial  transmission  of the 
SAE data. The investigator may change their opinion of causality in light of follow -up 
information and send a SAE follow -up report with the updated causality assessment. The 
causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
The investigator  should  consider  the following  before  reaching  a decision  on causality 
assessment:  
• Time  relationship  between  study  vaccine  injection and  event’s  onset.  
• Medical  history.  
• Study treatment.  
• Mechanism  of action of  study vaccine.  
• Class  effect.  
• Concomitant  treatments  in use. 
• Withdrawal  of study  treatment.  
• Lack  of efficacy/worsening  of existing  condition.  
• Possible  vaccine  enhancement  of COVID -19. 
• Erroneous  treatment  with study  medication  or concomitant  medication.  
• Protocol -related  process.  
8.2.1.2  Action  Taken  with  Study  Vaccine  Due to Adverse  Event  
The action  taken  with study  vaccine  should be recorded  using  one of the following:  
• Permanently  discontinued/withdrawn  (with  date).  
• Not applicable.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  53  
 
8.2.1.3  Other  Action  Taken  
Details  of any other actions  taken  should  be specified:  
• Specific  therapy/medication.  
• Surgical  or medical  procedure.  
8.2.1.4  AE Outcome  
Each  AE should  be rated  according  to one of the following outcomes:  
• Recovered/resolved.  
• Recovering/resolving.  
• Not recovered/not  resolved/ongoing.  
• Recovered  with sequelae/resolved  with sequelae.  
• Fatal.  
• Unknown.  
8.2.2 Time  Frame  for Collection  
All AEs captured  following  the procedures  listed  in the SOE  (Section  1.1) will be recorded  on 
the AE page of the eCRF.  
Medical  occurrences  that begin  prior  to study  vaccination  will be recorded  on the Medical 
History/Current Medical Conditions section of the eCRF and not in the AE section.  
All unsolicited  AEs of any severity  will be collected  from  the time of study  vaccination  through 
28 days after vaccination.  
All MAAEs  will be collected  through  28 days after vaccination  and only treatment -related 
MAAEs will be collected after Day 28 until EOS.  
All AESIs  will be collected  from  the time of study vaccination  until EOS.  
All SAEs  will be collected  from  signing  of informed  consent  until completion  of the EOS.  
All vaccine  administration  errors,  AEs,  SAEs,  cases  of multisystem  inflammatory  syndrome,  and 
all cases of COVID19 following vaccination must be reported per applicable local regulatory 
reporting guidance for safety events that occur in participants during the study if they meet the 
regulatory reporting criteria.  
At any time after completion  of the EOS  visit,  if an investigator  learns  of an SAE  that could 
reasonably  be considered related  to study  vaccine,  they should  promptly  notify  the Sponsor.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  54  
 
8.2.3 Classification  of Events  
8.2.3.1  Treatment -Emergent  Adverse  Events  
Treatment -emergent  adverse  events  are defined  as any AE occurring  or worsening  on or after the 
study vaccination.  
8.2.3.2  Adverse  Events  of Special  Interest  
Participants will be assessed for diagnosis of an AESI at all study contacts. AESIs include 
myocarditis  and/or  pericarditis,  other  PIMMCs,  and complications  specific  to COVID -19 (listed 
in Appendix 1 ), or other potential AEs that may be determined at any time by regulatory 
authorities as additional information concerning COVID -19 is obtained. Listings of AESI are 
presented in Appendix 1 . 
An AESI  must  be reported  as if it is an SAE  (Section 8.3). 
8.2.3.2.1  Myocarditis  and/or  Pericarditis  (CDC  Definition)  
Participants reporting signs or symptoms of myocarditis or pericarditis (eg, fatigue, acute chest 
pain, shortness of breath, etc., see Table 5 ) within 4 weeks after vaccination should be evaluated 
as soon as possible by a physician who should initiate diagnostic work up including but not 
limited to laboratory tests and initial cardiac evaluation. If probable or confirmed myocarditis 
and/or pericarditis is diagnosed after the initial evaluation, all efforts will be made to route the 
participants to be followed up preferentially by a cardiologist or pediatric cardiologist (as 
applicable) who should complete the initial evaluation and manage cases following current 
practice guidelines (eg, AHA or other national/local guidelines); this might include performing 
functional cardiac evaluation and follow up of the case until resolution (see Table 6 ). A Central 
Cardiac  Adjudication  Committee  has been  established  to adjudicate  suspected  myocarditis  and/or 
pericarditis cases in the clinical development plan of NVX -CoV2373. Outcomes of the 
adjudications will be communicated to the SMC (when applicable) and to the Sponsor.  
All myocarditis and/or pericarditis signs and symptoms, as well as all clinical evaluations, will  
be considered part of the study record and should be documented in the eCRF pages available to 
that end. Participants  with confirmed  myocarditis  or pericarditis  will be followed -up to document 
resolution of symptoms and/or abnormal test findings.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  55  
 
Table 5:  Case  Definitions  of Probable  and Confirmed  Myocarditis,  Pericarditis,  and 
Myopericarditis  
 
Condition  CDC  Definition  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute 
myocarditis  PROBABLE:  
Presence  of ≥ 1 new or worsening  of the following  clinical  symptoms:1 
• Chest  pain,  pressure,  or discomfort  
• Dyspnea,  shortness  of breath,  or pain with breathing  
• Palpitations  
• Syncope 
AND  
≥ 1 new finding  of 
• Troponin  level  above  upper  limit  of normal  (any type of troponin)  
• Abnormal  ECG  or rhythm  monitoring  findings  consistent  with myocarditis2 
• Abnormal  cardiac  function  or wall motion  abnormalities  on echocardiogram  
• cMRI  findings  consistent  with myocarditis3 
AND  
• No other  identifiable  cause  of the symptoms  and findings  
CONFIRMED:  
Presence  of ≥ 1 new or worsening  of the following  clinical  symptoms:1 
• Chest  pain,  pressure,  or discomfort  
• Dyspnea,  shortness  of breath,  or pain with breathing  
• Palpitations  
• Syncope 
AND  
≥ 1 new finding  of 
• Histopathologic  confirmation  of myocarditis4 
• cMRI  findings  consistent  with myocarditis3 in the presence  of troponin  level  above  upper 
limit of normal (any type of troponin)  
AND  
• No other  identifiable  cause  of the symptoms  and findings  
 
 
Acute 
pericarditis5 Presence  of ≥ 2 new or worsening  of the following  clinical  features:  
• Acute  chest  pain6 
• Pericardial  rub on exam  
• New  ST-elevation  or PR-depression  on ECG  
• New  or worsening  pericardial  effusion  on echocardiogram  or MRI 
Myopericarditis  This term may be used for patients  who meet  criteria  for both myocarditis  and pericarditis.  
Abbreviations:  AV = atrioventricular;  CDC  = Centers  for Disease  Control  and Prevention;  cMRI  = cardiac  magnetic 
resonance imaging; ECG = electrocardiogram; ESC = European Society of Cardiology; MRI = magnetic 
resonance imaging.  
1. Persons  who lack the listed  symptoms  but who meet  other  criteria  may be classified  as subclinical  myocarditis 
(probable or confirmed).  
2. To meet  the ECG  or rhythm  monitoring  criterion,  a probable  case must  include  at least one of 1) ST-segment  or 
T-wave abnormalities; 2) Paroxysmal or sustained atrial, supraventricular,  or ventricular  arrhythmias; or  3) AV 
nodal conduction delays or intraventricular conduction defects.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  56  
 
3. Using  either  the original  or the revised  Lake  Louise  criteria  (Ferreira  2018 ). 
4. Using  the Dallas  criteria  (Aretz  1987 ). Autopsy  cases  may be classified  as confirmed  clinical  myocarditis  on the 
basis of meeting histopathologic criteria if no other identifiable cause.  
5. Based  on the 2015  ESC Guidelines  for the diagnosis  and management  of pericardial  diseases  (Adler  2015 ). 
https://academic.oup.com/eurheartj/article/36/42/2921/2293375  
6. Typically  described  as pain made  worse  by lying  down,  deep  inspiration,  or cough,  and relieved  by sitting  up or 
leaning forward, although other types of chest pain might occur.  
Adapted  from  Gargano  2021 . 
 
 
Table 6:  Management  of Probable  or Confirmed  Myocarditis,  Pericarditis,  and 
Myopericarditis Cases  
 
Clinical 
Presentation  Procedures  
 
 
 
 
 
Probable or 
Confirmed 
Myocarditis, 
Pericarditis or 
Myopericarditis  1) ER visit and evaluation  by a physician  (as per national/local  guidelines):  
a. Diagnostic  work  up might  include:  
i. CBC,  Inflammatory  markers:  ESR,  CRP 
ii. Cardiac  markers:  Troponin  I, BNP,  NT-proBNP  
iii. Chest  radiograph  
iv. ECG  
2) Evaluation  by a cardiologist/pediatric  cardiologist  (as applicable)  
a. Follow  AHA  or other  national/local  guidelines  
i. Diagnostic  work  might  include:  
1. Stress  test echocardiogram  
2. Cardiac  biopsy  
3. cMRI  
4. Other  laboratory  or cardiac  assessment  tests as 
applicable  
b. Follow  up until resolution  
Abbreviations:  AHA  = American  Heart  Association;  BNP  = brain  natriuretic  peptide;  CBC  = complete  blood 
count; cMRI = cardiac magnetic resonance imaging; CRP = C -reactive protein; ECG = electrocardiogram;  
ER = emergency  room;  ESR = erythrocyte  sedimentation  rate; NT-proBNP  = N-terminal  pro b-type natriuretic 
peptide.  
 
8.2.3.3  Medically  Attended  Adverse  Events  
An MAAE  is defined  as an AE that leads  to an unscheduled  visit to a healthcare  practitioner.  
8.2.3.4  Reactogenicity  Symptoms  
On the day of vaccination, participants will remain in clinic (or under observation) for at least  
15 minutes to be observed for any immediate hypersensitivity and anaphylaxis reactions. Site 
specific  local  and general  systemic  reactogenicity  reactions  including  start and stop dates  will be 
recorded following vaccination.  
Participants will utilize their eDiary to record reactogenicity following vaccination. All 
participants  will be asked  to record  reactogenicity  following  vaccination  on Day 0 and then daily 
for an additional 6 days after vaccination. Study site personnel should regularly review the  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  57  
 
eDiary for completeness. Should any reactogenicity event extend beyond 6 days after 
vaccination, then it will be recorded using the Continuing Solicited AE form and followed to 
resolution per ICH guidelines for AE capture. Such AEs should be reported and managed as 
described  in Section  8.3. The toxicology  grading  scale  implemented  in the eDiary  for the study  is 
included in Appendix 2 . 
8.3 Reporting  Adverse  Events  
All SAEs must be reported according to ICH Good Clinical Practice (GCP) or local regulations, 
applying the regulation with the stricter requirements. Investigators and other study site 
personnel must inform appropriate Novavax representatives of any SAE that occurs during the 
course of the study, from the time of informed consent until the EOS visit, regardless of whether 
it is judged to be causally related to study vaccine or procedures. Notification must occur within 
24 hours  of when  they become  aware  of it. AESIs,  including  PIMMC,  myocarditis  or pericarditis 
and complications specific to COVID -19 are to be reported within these timelines on the 
SAE/AESI Report form. The investigator should make every effort to obtain follow -up 
information on the outcome until the event is considered resolved, chronic and/or stable.  
SAE reports received that may be attributed to both the study vaccine and an 
approved/authorized vaccine from a different manufacturer will be reported to local regulatory 
authorities as applicable. SAE reporting forms allow for the notation of other factors that may 
have impacted the investigator’s assessment of causality. Investigators will be instructed to 
utilize this section of the reporting form to note the impact of an approved/authorized vaccine 
from  a different  manufacturer  on the event,  if applicable.  Investigators  will be required  to report 
any SAEs in participants who received a different manufacturer’s approved/authorized vaccine 
to local health care and/or regulatory authorities as per the local regulatory guidelines.  
If a non-serious  AE becomes  serious,  this and other  relevant  follow -up information  must  also be 
provided  to Novavax Global  Vaccine  Safety  within  24 hours  as described  above.  The date when 
the AE becomes serious should be notated in the eCRF or on the SAE form.  
All SAEs and AESI will also be recorded in the eCRF. The investigator is responsible for 
informing the Independent Ethics Committee (IEC)/IRB of the SAE as per local requirements. 
Paper  SAE  forms  should  be completed  at the study  site and emailed  within  24 hours  of study  site 
awareness of the event to the Novavax Global Vaccine Safety mailbox:  
 
The report  form  should  be attached  to the email;  a notification  email  of the event  describing  it in 
the email text is not sufficient. There may be situations when an SAE has occurred, and the 
investigator has minimal information to include in the initial SAE report. However, it is very 
important that the investigator always makes an assessment of causality for every event prior to 
transmission of the SAE report form.  

SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  58  
 
Minimum  criteria  for a reportable  event  are: 
• Identifiable  patient  (participant  number)  
• A suspect  product  (ie, study  vaccine)  
• An identifiable  reporting  source  (investigator/study  site identification),  and 
• An event  or outcome  that can be identified  as serious.  
Follow -up information  on SAEs  must  also be reported  by the investigator  within  the same  time 
frames.  
8.3.1 Safety  Reporting  to Health  Authorities,  Independent  Ethics 
Committees/Institutional  Review  Boards,  and Investigators  
Novavax  or its designee will  be responsible  for notifications  of SAEs  and other  qualifying  events 
that are considered to be unexpected and related to study vaccine as expedited (eg, 7 - or 15 -Day 
reports to the relevant regulatory authorities and to participating investigators. In addition, 
Novavax or its designee will follow all applicable local and national regulatory requirements 
regarding safety reporting. Each investigator must comply with any applicable study local and 
national  regulatory  requirements  related  to the reporting  of SAEs  to the IRB/IECs  responsible  for 
reviewing the trial at their site, as well as the regulatory authority(ies) (where applicable).  
Timelines and responsibilities (Novavax and its designee) for expedited and periodic safety 
reporting to the Health Authorities, Independent Ethics Committees/ Institutional Review 
Boards,  and Investigators  are provided  in the Safety  Management  Plan as agreed  by the Syneos 
designee and Novavax.  
8.3.2 24/7 Medical  Emergency  Coverage  for Urgent  Protocol -related  Medical  Questions  
In a study -related health emergency, when assigned medical monitors for a study cannot be 
reached  by a caller,  for discussion  of urgent  medical  related  questions  an on-call physician  can 
be reached 24 hours 7 days a week (24/7) via Syneos Call Center:  
• Telephone:   
8.4 Pregnancy  
Pregnancy is not considered an AE unless there is a suspicion that an investigational vaccine 
may have interfered with the effectiveness of a contraceptive medication. Any pregnancy that 
occurs during study participation must be reported using the Pregnancy Assessment form. To 
ensure participant safety, each pregnancy must be reported to Novavax Global Vaccine Safety 
within 24 hours of learning of its occurrence. If pregnancy occurs, further vaccination will be 
discontinued. Pregnancy must be followed up to determine outcome (including spontaneous 
miscarriage,  elective  termination,  normal  birth,  or congenital  abnormality)  and the status  of both 
mother and child, even if the participant was discontinued from the study. Pregnancy  

SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  59  
 
complications  and elective  terminations  for medical  reasons  must  be reported  as an AE or SAE. 
Spontaneous miscarriages must be reported as an SAE.  
Any pregnancy brought to the investigator’s attention before the study is completed should be 
reported  to Novavax  Global  Vaccine  Safety  using  the Pregnancy  Assessment  form  provided  to 
sites.  
Any pregnancy  brought  to the investigator’s  attention  after the participant  has completed  the 
study but occurring while the participant was in the study must be promptly reported to:  
Novavax  Global  Vaccine  Safety:   
8.5 Overdose  or Misuse  
A drug overdose  is defined as the  accidental or  intentional use  of an IP or an administration error 
in an amount that is higher than is normally used. Every overdose must be reported to Novavax 
Global Vaccine Safety within 24 hours of awareness, using the details provided in Section 8.3 if 
the overdose  was associated  with an SAE.  Other  overdoses  and those  associated  with non-serious 
AEs should be reported in the AE eCRF. Only overdoses associated with a clinical SAE need to 
be reported as an SAE. The  quantity and details regarding the  excess dose  should be  documented 
in the eCRF.  
Overdose  in this study  is specifically  defined  as any dose greater  than the intended  protocol  dose 
(Section 7). In case of overdose, it is recommended that the participant be monitored for any 
signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment be 
administered immediately. Note that administration of the “wrong” vaccine is a protocol 
deviation, but not, in the absence of associated AE, an SAE.  
9 ANALYSIS  
9.1 Sample  Size Calculations  
The sample size for this study is based on clinical and practical considerations and not on a 
formal statistical power calculation. The sample size is considered sufficient to evaluate the 
objectives of the study. With 200 participants in each treatment group, there is a greater than 
99.9%  probability  to observe  at least 1 subject  with an AE if the true incidence  of the AE is 5% 
and an 86.6% probability if the true incidence of the AE is 1%.  
9.2 Analysis  Sets 
The following  analysis  sets are identified  for analysis.  

SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  60  
 
9.2.1 All Randomized  Participants  Analysis  Set 
The All Randomized Participants Analysis Set will include all participants who are 
randomized/enrolled,  regardless  of whether  they actually  received  any study  vaccine.  The All 
Randomized Participants Analysis Set will be  used for  participant disposition summaries and 
will be analyzed according to the treatment as randomized/enrolled.  
9.2.2 Full Analysis  Set 
The Full Analysis Set (FAS) will include all participants who are randomized/enrolled and 
received  at least 1 dose of study  vaccine,  regardless  of protocol  violations  or missing  data.  The 
FAS may be the secondary analysis set used for any immunogenicity analyses and will be 
analyzed according to the treatment as randomized.  
9.2.3 Safety  Analysis  Set 
The Safety  Analysis  Set will include  all participants  who provide  consent, are  randomized, and 
receive  at least 1 dose of study  vaccine.  Participants  in the Safety  Analysis  Set will be analyzed 
as actually treated.  
9.2.4 Per-Protocol  Analysis  Set 
The Per -Protocol (PP) Analysis Set will be determined for each strain, serology assay and study 
visit.  The PP Analysis  set will include  all participants  who receive  the full prescribed  regimen  of 
the study  vaccine  up to the visit according  to protocol,  have  serology  results  for baseline  and the 
time point  analyzed,  are PCR  negative  at baseline  for SARS -CoV -2, and have  no major  protocol 
violations  or an event  (eg, COVID -19 infection)  that are considered clinically  relevant  to impact 
immunogenicity response as determined prior to database lock.  
Within  the PP Analysis  Set there  are 3 subsets  defined:  
9.2.4.1  Anti -S Protein  IgG Serology  Subset  
All participants  in the PP Analysis  Set who are tested  for anti-S protein  IgG serology  using 
ELISA at each timepoint will be included in this subset.  
9.2.4.2  Neutralization  Assay  Subset  
All participants  in the PP Analysis  Set who are tested  using  the neutralization  assay  at each 
timepoint will be included in this subset.  
9.2.4.3  hACE2  Receptor -Binding  Inhibition  Assay  Subset  
All participants  in the PP Analysis  Set who are tested  for hACE2  receptor -binding  inhibition 
titers at each timepoint will be included in this subset.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  61  
 
9.2.4.4  Mucosal  hACE2  Receptor  Binding  Inhibition  Assay  Subset  
All participants  in the PP Analysis  Set who are tested  for mucosal  IgA-mediated  hACE2  receptor 
binding inhibition titers at each time point will be included in this subset.  
9.3 Analyses  to be Performed  
9.3.1 Safety  Analysis  
All safety  analyses  will be descriptive  and conducted  using  the Safety  Analysis  Set. Listings  will 
be provided for all safety parameters collected.  
9.3.1.1  Solicited  Adverse  Events  
The number  and percentage  of participants  with solicited  injection  site and systemic  AEs through 
7 days after vaccination will be summarized overall and by vaccine group and by the worst 
maximum toxicity grade over 7 days. The durations of solicited local and systemic AEs after 
vaccination within the 7 Day diary period and entire safety follow -up period will also be 
summarized by vaccine group.  
9.3.1.2  Unsolicited  Adverse  Events  
Unsolicited  AEs will be coded  by system  organ  class  (SOC)  and preferred  term (PT) using 
Medical Dictionary for Regulatory Activities (MedDRA).  
Unsolicited AEs will be summarized according to the periods described in Section 8.2.2  both 
overall  and by vaccine  group  and by SOC/PT,  as well as by severity  and relationship  to the study 
vaccine to present the number and percentage with corresponding exact 95% CIs using the 
Clopper -Pearson  method. For  multiple  occurrences  of an adverse  event  in the same  participant,  a 
participant will be counted only once, using the most severe or most related occurrence for the 
summarization by severity or relationship to the study vaccine, respectively.  
All MAAEs (only related MAAEs beyond 28 days following vaccination), AESIs (predefined 
list), and SAEs  throughout  the study  (up to the time of pre-planned  analyses)  will be summarized 
overall and by vaccine group as well as by severity.  
9.3.1.3  Prior  and Concomitant  Medications  and Vaccinations  
Prior  and concomitant  medications  and vaccinations  will be summarized  overall  and by vaccine 
group and preferred drug name as coded using the World Health Organization (WHO) drug 
dictionary for all participants on the Safety Analysis Set.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  62  
 
9.3.1.4  Extent  of Exposure  
The number of participants receiving study vaccine will be presented by vaccine group on the 
Safety Analysis Set. Below information will also be summarized by vaccine group: whether the 
vaccine is administered and the reason if not, whether the vaccine is administered per protocol 
and the reason  if not, whether  full dose is administered  and the reason  if not, anatomical  location 
of the administration, follow -up time since the first vaccination.  
9.3.1.5  Vital  Sign  Measurements  and Physical  Examination  
Listings  will be provided  for vital sign measurements  and physical  examinations  data collected.  
9.3.2 Immunogenicity  Analysis  
All immunogenicity  analyses  will be descriptive.  Listings  will be provided  for all 
immunogenicity data collected.  
9.3.2.1  Analysis  of Primary  Immunogenicity  Endpoints  
The analysis  of the primary  immunogenicity  endpoints  will be performed  using  the Per-Protocol 
(PP) Analysis Set and the Neutralization Assay Subset.  
The primary immunogenicity endpoints focus on NAb against the Omicron XBB1.5 strain at  
Day 28 following initial study vaccination. Neutralizing antibodies (NAb) GMT and GMFR 
(compared to Day 0) to the Omicron XBB.1.5 strain and corresponding 95% CIs, are 
summarized at Day 28 by vaccine group. GMT is calculated as the antilog of the mean of log - 
transformed titer values. GMFR is the antilog of the mean of log -transformed fold -rises. The 
95% CIs are calculated based on the  t-distribution of  the log transformed titer  or fold-rise values, 
then back  transformed  to the original  scale.  The between -group  ratio of GMT  (GMTR)  at Day 28 
and the two-sided  95% CIs are computed  using  the analysis  of covariance  with the vaccine  group 
as the fixed effect and the titer at Day 0 (ie, adjusted for intergroup variation in baseline [pre - 
vaccination] titers) as the covariate. The mean difference between vaccine groups and the 
corresponding CI limits will then be exponentiated to obtain the ratio of NAb GMTs and the 
corresponding 95% CIs. There is no formal evaluation of statistical hypotheses.  
Seroresponse is defined as post -vaccination titer ≥4 -fold increase from baseline value. 
Participants with a baseline value below the lower limit of quantitation (LLOQ) will be 
considered achieving seroresponse only if the post -baseline value is greater than or equal to 4 
times  the LLOQ.  The percentage  of participants  achieving  seroresponse  rate (SRR)  is calculated 
at Day 28. 95% CIs of the SRR will be calculated based on the exact Clopper -Pearson method. 
Difference  in SRR  will be calculated  at Day 28, with  the 95% CI for the difference  based  on the 
method of Miettinen and Nurminen.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  63  
 
9.3.2.2  Analysis  of Secondary  Immunogenicity  Endpoints  
For the secondary immunogenicity endpoints of NAb response against the Omicron XBB.1.5 
strain over time, analyses will be performed using the Per -Protocol (PP) Analysis Set and the 
Neutralization Assay Subset. NAb GMTs to the Omicron XBB.1.5 strain and 95% CIs are 
summarized  at Day 0, 90, and 180. NAb  GMFR  (compared  to Day 0) and SRR  to the Omicron 
XBB.1.5 strain and 95% CIs are summarized at Day 90 and 180.  
For the secondary immunogenicity endpoints of IgG antibody levels against the Omicron 
XBB.1.5 strain over time, analyses will be performed using the Per -Protocol (PP) Analysis Set 
and the Anti -S Protein IgG Serology Subset. IgG GMEUs to the Omicron XBB.1.5 strain and 
95% CIs are summarized  at Day 0, 28, 90, and 180. IgG GMFR  (compared  to Day 0) and SRR  to 
the Omicron XBB.1.5 strain and 95% CIs are summarized at Day 28, 90 and 180.  
Summary  statistics  used to evaluate  secondary  immunogenicity  objectives  are summarized  by 
vaccine group. There is no formal evaluation of statistical hypotheses.  
9.3.2.3  Analysis  of Exploratory  Immunogenicity  Endpoints  
For the exploratory  immunogenicity  endpoints  of NAb  and IgG antibody  responses  against  the 
ancestral (Wuhan) strain over time, analyses will be performed using the Per -Protocol (PP) 
Analysis Set, and within the  Neutralization Assay Subset and the  Anti-S Protein IgG Serology 
Subset respectively. NAb GMTs and IgG GMEUs to the ancestral (Wuhan) strain with 
corresponding 95% CIs are summarized at Day 0, 28, 90, and 180. NAb and IgG GMFR 
(compared  to Day 0) and SRR  with corresponding  95% CIs are  summarized  at Day 28, 90 and 
180. The endpoints  will be  analyzed  by vaccine  group.  
For the exploratory immunogenicity endpoints of antibody responses in a hACE2 receptor 
binding inhibition assay against the Omicron XBB.1.5 and ancestral (Wuhan) strains over time, 
analyses will be performed using the Per -Protocol (PP) Analysis Set and the hACE2 Receptor - 
Binding Inhibition Assay Subset. Serum hACE2 GMTs to the Omicron XBB.1.5 and ancestral 
(Wuhan)  strains  with corresponding  95% CIs are summarized  at Day 0, 28, 90, and 180. hACE2 
GMFR (compared to Day 0) and SRR to the Omicron XBB.1.5 and ancestral (Wuhan) strains 
with corresponding 95% CIs are summarized at Day 28, 90 and 180. The endpoints will be 
analyzed by vaccine group.  
Mucosal IgA -mediated hACE2 receptor inhibition assay responses to the Omicron XBB.1.5 and 
ancestral  (Wuhan)  strains  will be summarized  using  the PP Analysis  Set and the Mucosal  hACE2 
Receptor -Binding Inhibition Assay Subset. GMTs to the Omicron XBB.1.5 and ancestral 
(Wuhan) strains with corresponding 95% CIs will be summarized at Day 0 and Day 28. GMFR 
(compared to Day 0) and SRR with corresponding 95% CIs will be summarized at Day 28.  
The other  exploratory Immunogenicity  analyses  will be defined  in the SAP.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  64  
 
9.3.3 Other  Exploratory  Analyses  
The other  exploratory  analyses  will be defined  in the SAP.  
9.4 Other  Statistical  Considerations  
9.4.1 Population  Analysis  
9.4.1.1  Disposition  and Protocol  Compliance  
The number  of participants  consented,  randomized/enrolled,  and vaccinated  will be presented  by 
vaccine group for the All Randomized Participants Analysis Set.  
The number (percentage) of participants in the All Randomized Participants Analysis Set, FAS, 
Safety  Analysis  Set, and PP Analysis  Set for the primary  endpoint  only who have  completed  the 
study up to the time of pre -planned analyses (including EOS for the final analysis) will be 
summarized by vaccine group.  
The number  (percentage)  of participants  who discontinue  the study  prior  to EOS  and the reason 
for discontinuation (eg, AE, investigator decision, lost to follow -up, non -compliance, etc.) will 
be presented by vaccine group.  
The number  (percentage)  of participants  with major  protocol  deviation(s)  recorded  throughout 
the study will be summarized by vaccine group and protocol deviation category.  
9.4.1.2  Demographics  and Baseline  Characteristics  
Baseline  demographic  and background  characteristics  (eg, age, gender,  ethnicity,  race,  height, 
weight,  and BMI  [derived])  will be summarized  by vaccine  group  for the FAS,  Safety,  and PP 
Analysis Sets. Frequencies and percentages will be presented for categorical variables.  
Continuous  variables  will be summarized  using  descriptive  statistics  (total  number  of 
participants, mean and standard deviation, median, minimum, and maximum).  
Medical history will be coded using MedDRA terms. Baseline medical history recorded at 
Screening will be summarized by the study vaccine group and by MedDRA SOC/PT for all 
participants  in the Safety  Analysis  Set. Within  each SOC  and PT, the number  and percentage  of 
participants with at least one medical history event will be presented, respectively. Multiple 
events within a given SOC and PT for a participant will be counted once.  
The characterization  of baseline  immunity  will be summarized,  to include  tabulation  of PCR  and 
anti-N results at Day 0, the  brand(s)  of mRNA  vaccine  previously received, the  number  of doses 
received, and the length of the interval between last mRNA vaccine and study investigational 
vaccine.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  65  
 
9.4.1.3  Listings  of Population  Analysis  data 
Listings  of all data used for analysis  of population parameters  will be created.  
9.5 Planned  Interim Analyses  
A formal  interim  analysis  will be carried  out when  the complete  data is available  to evaluate  the 
primary endpoint. A set of secondary and exploratory endpoints will also be analyzed at this 
time, dependent on the availability of data. The database extract is expected to include 
immunogenicity data and safety data through Day 28. An independent statistics organization or 
the internal statistics team will perform the analysis and receive unblinded data at the time of 
analyses, following final determination of participant exclusions from analysis populations and 
database extract. At the time of Day 28 data extract with receipt of the randomization list, the 
Sponsor will be unblinded at the participant level to prepare for regulatory submissions.  
9.6 Specified  Analyses  for Independent  Data  Monitoring  Committee  Review  
Data  surrounding  suspected  cases  of myocarditis/pericarditis  will be provided  to the appointed 
Central Cardiac Adjudication Committee as needed  
9.7 Procedures  for Reporting  Changes  to the Planned  Analysis  
Changes  to the analyses  or analysis  methods  specified  in the protocol  will be documented  in the 
SAP and in the clinical study report.  
10 ETHICAL  CONSIDERATIONS  
10.1 Good  Clinical  Practice  
The investigator agrees that the study will be conducted according to the principles of ICH 
E6(R2). The investigator will conduct all aspects of this study in accordance with all national, 
state,  and local  laws or regulations.  The study  will be conducted  in compliance  with the protocol, 
current GCP guidelines – adopting the principles of the Declaration of Helsinki – and all 
applicable regulatory requirements.  
Prior  to study  initiation,  the protocol  and the informed  consent  documents  will be reviewed  and 
approved  by the sponsor  (or designee)  and an appropriate  ethics  committee.  Any amendment  to 
the protocol or  consent materials must also be  approved by the  study sponsor  (or designee)  and 
IRB and must be submitted/notified to the regulatory authority, as required, before they are 
implemented.  
10.2 Ethics  Review  
Prior  to the start of the study,  the investigator  is responsible  for ensuring  that the protocol  and 
consent form have been reviewed and approved by a relevant IRB. The IRB shall be  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  66  
 
appropriately  constituted  and perform  its functions  in accordance  with ICH GCP  and local 
requirements as applicable.  
The IRB shall  approve  all protocol  amendments  (except  for logistical  or administrative  changes), 
written informed consent documents and document updates, participant recruitment procedures 
(eg, advertisements), written information to be provided to the participants, IB, available safety 
information, information about payment and compensation available to participants, the 
investigator's curriculum vitae and/or other evidence of qualifications and any other documents 
requested by the IRB and Regulatory Authority (Competent Authority) as applicable.  
10.3 Informed  Consent  
The nature  and purpose  of the study  shall  be fully  explained  to each participant.  They  must  be 
informed that participation is voluntary.  
Documentation of informed consent (either written or via eConsent) must be obtained from each 
participant prior to any study procedures being performed. The process of obtaining informed 
consent must be documented in the participant’s source documents. The authorized person 
obtaining the informed consent must also sign the ICF, and a copy of the ICF must be provided 
to the participant.  Participants  must  be re-consented  to the most  current  version  of the ICF during 
their participation in the study.  
Participants  will be requested  to provide  the name  and contact  information  for an emergency 
contact and to provide consent for future testing to support establishment of correlates of 
protection against SARS -CoV -2 infection and disease (see Section 6.2 regarding sample 
retention).  
The consent documents to be used for the study shall include all the elements of informed 
consent  as outlined  in accordance  with ICH GCP  and local  requirements  as applicable  and be 
reviewed and approved by the appropriate IRB prior to use.  
10.4 Data  Privacy  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a 
manner designed to maintain participant confidentiality. All records will be kept in a secure 
storage area with limited access. Clinical information will not be released without the written 
permission  of the participant,  except  as necessary  for monitoring  and auditing  by the sponsor,  its 
designee, relevant regulatory authority(ies), or the IRB.  
The investigator and all employees and co -workers involved with this study may not disclose or 
use for any purpose other than performance of the study, any data, record, or other unpublished, 
confidential  information  disclosed  to those  individuals  for the purpose  of the study.  Prior  written 
agreement from the sponsor or its designee must be obtained for the disclosure of any said 
confidential information to other parties.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  67  
 
11 OVERSIGHT  
11.1 Quality  Control  and Assurance  
The Sponsor/designee shall implement and maintain quality control and quality assurance 
procedures with written standard operating procedures (SOPs) to ensure that the study is 
conducted  and data are generated,  documented,  and reported  in compliance  with the protocol, 
ICH GCP, and applicable regulatory requirements.  
This study  shall  be conducted  in accordance  with the provisions  of the Declaration  of Helsinki 
(October 2013) and ICH GCP (CPMP/ICH/135/95 and updates).  
The investigator  will be responsible  for the following:  
• Providing written summaries of the status of the study to the IRB annually or more 
frequently  in accordance  with the requirements,  policies,  and procedures  established  by 
the IRB.  
• Notifying  the IRB of SAEs  or other  significant  safety  findings  as required  by IRB 
procedures.  
The investigator  may not deviate  from  the protocol  without  a formal  protocol  amendment  having 
been established and approved by an IRB, except when necessary to eliminate immediate 
hazards to the participant or when the change(s) involve(s) only logistical or administrative 
aspects of the study. Any deviations may result in the participant having to be withdrawn from 
the study and render that participant non -evaluable.  
The identification and reporting of serious breaches of ICH GCP or the protocol to the 
Regulatory  Authorities  and Ethics  Committees  will be conducted  according  to local  SOPs  and 
regulations.  
11.1.1  Monitoring  
The Syneos clinical monitor, as a representative of the sponsor, is obligated to follow the study 
closely. In doing so, the monitor will visit the investigator and study site at periodic intervals as 
defined in the study monitoring and oversight plans in addition to maintaining necessary 
telephone  and email  contact.  The monitor  will maintain  current  personal  knowledge  of the study 
through observation, review of study records and source documentation, and discussion of the 
conduct of the study with the investigator and personnel.  
All aspects  of the study  will be carefully  monitored  by the sponsor  or its designee  for compliance 
with applicable government regulation with respect to current ICH E6(R2)guidelines and 
standard operating procedures.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  68  
 
11.1.2  Audits  
The investigator and institution involved in the study will permit study -related monitoring, 
audits,  IRB review,  and regulatory  inspections  by providing  direct  access  to all study  records.  In 
the event of an audit, the investigator agrees to allow the sponsor, their representatives, or the 
regulatory authority access to all study records.  
The investigator  should  promptly  notify  the sponsor  of any audits  scheduled  by any regulatory 
authorities and promptly forward copies of any audit reports received to the sponsor.  
11.1.3  Protocol  Deviations  
The investigator or designee must document and explain in the participant’s source 
documentation any deviation from the approved protocol. The investigator may implement a 
deviation from, or a change to, the protocol to eliminate an immediate hazard to study 
participants without prior IRB approval. As soon as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol amendments 
should  be submitted  to the IRB for review  and approval,  to the sponsor  for agreement,  and to the 
regulatory authorities, if required.  
A protocol  deviation  is any change,  divergence,  or departure  from  the study  design  or procedures 
defined in the protocol. An important deviation (sometimes referred to as a major or significant 
deviation) is a subset of protocol deviations that leads to a participant being discontinued from 
the study or significantly affects the participant’s rights, safety, or well -being and/or the 
completeness, accuracy, and reliability of the study data. An important deviation can include 
nonadherence  to inclusion  or exclusion  criteria  or nonadherence  to regulatory  authority  including 
ICH E6(R2) guidelines.  
Protocol deviations will be documented by the clinical monitor throughout the course of 
monitoring  visits.  The investigator  will be notified  in writing  by the monitor  of deviations.  The 
IRB should be notified of all protocol deviations, as appropriate, in a timely manner.  
Review  and categorization  of protocol  deviations  will occur  prospectively  during  the study  prior 
to database lock(s).  
11.1.4  Records  
11.1.4.1  Data  Capture  and Management  
All required study data will be entered by study site personnel in the eCRF or by study 
participants  in the eDiary  created  for the study.  Data  required  according  to this protocol  will be 
recorded by study site  personnel via  data entry into the  internet -based EDC software  system or 
by study participant via the eDiary. The investigator shall ensure that all data from participant 
visits are promptly entered into the eCRFs in accordance with the specific instructions given.  
The investigator  must  sign each eCRF  to verify  the integrity  of the data recorded.  All internal  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  69  
 
Syneos  and external  study  site personnel  seeking  access  to the eCRF  are supported  by a Service 
Desk (if applicable). At the end of the study all data captured electronically will be provided to 
the investigator on CD ROM for archiving at the study site.  
The Sponsor  or designee  is responsible  for the data management  of this study  including  quality 
checking of the data.  
11.1.4.2  Source  Documentation  
The investigator must maintain source documents, such as laboratory reports, consultation 
reports,  reactogenicity  diaries  and complete  medical  history  and physical  examination  reports. 
All information in the CRF must be traceable to the participant’s source documents.  
The investigator/institution  shall  provide  direct  access  to source  data/documents  for study  related 
monitoring, audits, IRB review, and regulatory inspection.  
11.1.4.3  Records  Retention  
The investigator/institution should maintain the study documents as specified in the ICH 
guidelines on GCP and as required by the applicable regulatory requirements. The 
investigator/institution  should  take measures  to prevent  accidental  or premature  destruction  of 
these documents.  
It is the Sponsor’s  responsibility  to inform  the investigator/institution  as to when  these 
documents no longer need to be retained.  
11.2 Study  Termination  or Study  Site Closure  
Although  the sponsor  has every  intention  of completing  the study,  they reserve  the right  to 
discontinue it at any time for clinical or administrative reasons.  
The end of the study is defined as the date on which the last participant completes the last study 
visit (including  the EOS  visit and any additional  long-term follow -up). Any additional  long-term 
follow -up that is required for monitoring of the resolution of an AE or finding may be appended 
to the clinical study report.  
12 PUBLICATION  POLICY  
The Sponsor  shall  retain  the ownership  of all data.  When  the study  is complete  the Sponsor  shall 
arrange the analysis and tabulation of data. A clinical study report shall then be prepared, which 
may be used for publication, presentation at scientific meetings or submission to regulatory 
authorities.  
The Sponsor  will generally  support  publication  of multicenter  studies  only in their entirety  and 
not as individual study site data. In this case, a coordinating investigator will be designated by  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  70  
 
mutual agreement. Authorship will be determined by mutual agreement and in line with the 
International Committee of Medical Journal Editors authorship agreements. Authors will be 
provided  reasonable  access  to all study  data,  statistical  tables,  figures, and  relevant  reports  and 
will have  the opportunity  to review  complete  study  results.  All proposed  publications  based  on 
this study must be participant to the Sponsor's approval requirements.  
The Sponsor assures that the key design elements of this protocol will be posted in a publicly 
accessible  database  such as clinicaltrials.gov.  In addition,  upon  study  completion  and finalization 
of the study report, the results of this trial will be submitted for publication and/or posted in a 
publicly accessible database of clinical trial results.  
13 FINANCING  AND  INSURANCE  
The investigator is required to provide financial disclosure information to allow the sponsor to 
submit the complete and accurate certification or disclosure statements required under US Title 
21 CFR Part 54 and local regulations. In addition, the investigator must provide to the sponsor a 
commitment  to promptly  update  this information  if any relevant  changes  occur  during  the course 
of the investigation and for 1 year following the completion of the study.  
Neither  the sponsor  nor the CRO  nor the study  site is financially  responsible  for further  testing  or 
treatment of any medical condition that may be detected during the screening process. In 
addition, in the absence of specific arrangements, neither the sponsor nor the CRO nor the study 
site is financially responsible for further treatment of the disease under study.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  71  
 
14 REFERENCES  
Adler  2015  
Adler  Y, Charron  P, Imazio  M, et al. 2015  ESC Guidelines  for the diagnosis  and management  of 
pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases 
of the European Society of Cardiology (ESC)Endorsed by: The European Association for 
Cardio -Thoracic Surgery (EACTS). Eur Heart J. 2015 Nov 7;36(42):2921 -2964  
Aretz  1987  
Aretz  HT, Billingham  ME, Edwards  WD,  et al. Myocarditis.  A histopathologic  definition  and 
classification. Am J Cardiovasc Pathol. 1987 Jan; 1 (1):3 -14. 
CDC  2022  
Centers  for Disease  Control  and Prevention  (CDC).  SARS -CoV -2 Variant  Classifications  and 
Definitions. 26 Apr 2022. Available at: https:// www.cdc.gov/coronavirus/2019 - 
ncov/variants/variant -classifications.html  
CDC  2023  
Centers  for Disease  Control  and Prevention.  COVID  Data  Tracker.  Atlanta,  GA: US Department 
of Health and Human Services, CDC; 2023, April 28. Available at: https://covid.cdc.gov/covid - 
data-tracker/#variant -proportions  
CDC  2021  
Centers  for Disease  Control  and Prevention.  Clinical  considerations:  myocarditis  and pericarditis 
after receipt of mRNA COVID -19 vaccines among adolescents and young adults. Available at: 
https:// www.cdc.gov/vaccines/covid -19/clinical -considerations/myocarditis.html.  
DAIDS  2017  
Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), 
National  Institutes  of Health  (NIH),  US Department  of Health  and Human  Services.  Division  of 
AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. July 2017. 
Available at: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf  
Dunkle  2021  
Dunkle  LM, Kotloff  KL, Gay MD, et al. Efficacy  and safety  of NVX -CoV2373  in adults  in the 
United States and Mexico. New Engl J Med. 2022 Feb(386):531 -543. 
doi10.1056/NEJMoa2116185.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  72  
 
FDA  2007  
U.S. Food  and Drug  Administration,  Center  for Biologics  Evaluation  and Research  (US). 
Guidance  for industry:  Toxicity  grading  scale  for healthy  adult  and adolescent  volunteers 
enrolled in preventive vaccine clinical trials. September 2007. Available at: 
https:// www.fda.gov/media/73679/download  
Ferreira  2018  
Ferreira VM, Schulz -Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in 
Nonischemic  Myocardial  Inflammation:  Expert  Recommendations.  Am Coll Cardiol.  2018  Dec 
18;72(24):3158 -3176.  
Garcia -Beltran  2021  
Garcia -Beltran  WF, St Denis  KJ, Hoelzemer  A, et al. mRNA -based  COVID -19 vaccine  boosters 
induce neutralizing immunity against SARS -CoV -2 Omicron variant. medRxiv [Preprint]. 2021 
Dec 14:2021.12.14.21267755. doi: 10.1101/2021.12.14.21267755  
Gargano  2021  
Gargano  JW, Wallace  M, Hadler  SC, Langley  G, Su JR, Oster  ME, et al. Use of mRNA  COVID - 
19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory 
committee on immunization practices - United States, June 2021. MMWR Morb Mortal Wkly 
Rep. 2021 Jul 9;70(27):977 -82. 
Habibzadeh  2020  
Habibzadeh  P, Stoneman  EK. The novel  coronavirus:  a bird’s  eye view.  Int J Occup  Environ 
Med. 2020;11(2):65 -71. 
Heath  2021  
Heath  PT, Galiza  EP, Baxter  DN, et al. Safety  and efficacy  of the NVX -CoV2373  Covid -19 
vaccine. N Engl J Med 2021;385:1172 -1183.  
Keech  2020  
Keech  C, Albert  G, Cho I, et al. Phase  1-2 trial of a SARS -CoV -2 recombinant  spike  protein 
nanoparticle vaccine. New Engl J Med. 2020;383:2320 -2332.  
Lambert  2020  
Lambert  P-H, Ambrosino  DM, Andersen  SR, et al. Consensus  summary  report  for CEPI/BC 
March 12 -13, 2020 meeting: Assessment of risk of disease enhancement with COVID -19 
vaccines. Vaccine. 2020;38(31):4783 -4791.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  73  
 
Law  2021  
Law YM, Lal AK, Chen S, et al. Diagnosis and management of myocarditis in children: a 
scientific  statement  from  the American  Heart  Association.  Circulation.  2021;144:e123 -e135.  
Mallory  2022  
Mallory  RM, Formica  N, Pfeiffer  S, et al. Safety  and immunogenicity  following  a homologous 
booster dose of a SARS -CoV -2 recombinant spike protein vaccine (NVX -CoV2373): a 
secondary analysis of a randomised, placebo -controlled, phase 2 trial. Lancet Infect Dis. 2022 
Nov;22(11):1565 -1576. doi: 10.1016/S1473 -3099(22)00420 -0. 
Marks  2022  
Marks,  P. (2022).  "Coronavirus  (COVID -19) update:  FDA  recommends  inclusion  of omicron 
BA.4/5 component for COVID -19 vaccine booster doses". Available at: 
https:// www.fda.gov/news -events/press -announcements/coronavirus -covid -19-update -fda- 
recommends -inclusion -omicron -ba45 -component -covid -19-vaccine -booster ." 
Novavax  2022  
Clinical  Investigator’s  Brochure  for SARS -CoV -2 Recombinant  Spike  Protein  Nanoparticle 
Vaccine (SARS -CoV -2 rS). Novavax, 2022.  
Qu 2023  
Qu P, Faraone  JN, Evans  JP, et al. Extraordinary  Evasion  of Neutralizing  Antibody  Response  by 
Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants. bioRxiv [Preprint]. 2023 Jan 
17:2023.01.16.524244. doi: 10.1101/2023.01.16.524244.  
Sheikh -Mohamed  2022  
Sheikh -Mohamed  S, Isho B, Chao  Y.C.  et al. Systemic  and mucosal  IgA responses  are variably 
induced in response to SARS -CoV -2 mRNA vaccination and are associated with protection 
against subsequent infection. Mucosal Immunology (2022) 15:799 –808. 
Shinde  2021  
Shinde  V, Bhika  S, Hoosain  Z, Archary  M, et al. Efficacy  of NVX -CoV2373  Covid -19 Vaccine 
against the B.1.351 Variant. New Engl J Med. Preprint 2021 May 05 DOI: 
10.1056/NEJMoa2103055.  
Su 2016  
Su S, Wong  G, Shi W, et al. Epidemiology,  genetic  recombination,  and pathogenesis  of 
coronaviruses. Trends Microbiol. 2016;24(6):490 -502. 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  74  
 
Tavares  2013  
Tavares F, Keyser F, Lambert P, et al. Optimal approaches to data collection and analysis of 
potential  immune  mediated  disorders  in clinical  trials  of new vaccines.  Vaccine.  2013;31:1870 - 
76. 
Yue 2023  
Yue C, Song  W, Wang  L, et al. ACE2  binding  and antibody  evasion  in enhanced  transmissibility 
of XBB.1.5. Lancet Infect Dis. 2023 Mar;23(3):278 -280. doi: 10.1016/S1473 -3099(23)00010 -5. 
Zhang  2022  
Zhang  X, Chen  LL, Ip JD, et al. Omicron  sublineage  recombinant  XBB  evades  neutralising 
antibodies in recipients of BNT162b2 or CoronaVac vaccines. Lancet Microbe. 2023 
Mar;4(3):e131. doi: 10.1016/S2666 -5247(22)00335 -4. 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  75  
 
15 APPENDICES  
APPENDIX  1: LISTINGS  OF ADVERSE  EVENTS  OF SPECIAL  INTEREST  
Because  it has been  hypothesized  that immunizations  with or without  adjuvant  may be associated 
with autoimmunity, regulatory authorities have requested that Novavax instruct investigators to 
be especially vigilant regarding the PIMMCs listed in Table 7 . Note that this regulatory request  
is not specific to Novavax’s SARS -CoV -2 rS or Matrix -M adjuvant; and there is no current 
evidence to suggest that the study vaccines in this protocol are, or are not, associated with these 
illnesses. The list is not intended to be exhaustive, nor does it exclude the possibility that other 
diagnoses may be AESI.  
 
Table  7: Potential  Immune -Mediated  Medical  Conditions  
 
Categories  Diagnoses  (as MedDRA  Preferred  Terms)  
Neuroinflammatory 
Disorders:  Acute  disseminated  encephalomyelitis  (including  site-specific  variants:  eg, non- 
infectious encephalitis, encephalomyelitis, myelitis, cranial nerve disorders 
including paralyses/paresis (eg, Bell’s palsy), ascending flaccid paralysis, 
generalized convulsion, Guillain -Barre syndrome (including Miller Fisher 
syndrome and other variants), immune -mediated peripheral neuropathies and 
plexopathies (including chronic inflammatory demyelinating polyneuropathy, 
multifocal motor neuropathy and polyneuropathies assoc iated with monoclonal 
gammopathy), myasthenia gravis, multiple sclerosis, narcolepsy, optic neuritis, 
transverse myelitis, uveitis.  
Musculoskeletal  and 
Connective Tissue 
Disorders:  Antisynthetase syndrome, dermatomyositis, juvenile idiopathic arthritis (including 
Still’s disease), connective tissue disorder, polymyalgia rheumatic, polymyositis, 
psoriatic arthropathy, polychondritis, rheumatoid arthritis, scleroderma (including 
diffuse systemic form and CREST syndrome), spondyloarthritis (including 
ankylosing spondylitis, reactive arthritis [Reiter's Syndrome], axial 
spondyloarthritis,  juvenile  spondyloarthritis  and undifferentiated  spondyloarthritis), 
systemic lupus erythematosus, sys temic sclerosis, Sjogren’s syndrome.  
Vasculitides:  Large vessels vasculitis (including giant cell arteritis such as Takayasu's arteritis 
and temporal arteritis), medium sized and/or small vessels vasculitis (including 
polyarteritis nodosa, Kawasaki's disease, microscopic polyangiitis, Wegener's 
granulomatosis, Churg –Strauss syndrome [allergic granulomatous angiitis], 
Buerger’s  disease  [thromboangiitis  obliterans],  Eosinophilic  granulomatosis  with 
polyangiitis, necrotizing vasculitis and ANCA -positive vasculitis [type 
unspecified], Henoch -Schonlein purpura, Behcet's syndrome).  
Gastrointestinal  Disorders:  Crohn’s  disease,  celiac  disease,  ulcerative  colitis,  ulcerative  proctitis.  
Hepatic  Disorders:  Autoimmune  hepatitis,  autoimmune  cholangitis,  cholangitis  sclerosing  primary 
biliary cirrhosis.  
Renal  Disorders:  Autoimmune  glomerulonephritis  (including  IgA nephropathy,  glomerulonephritis 
rapidly progressive, membranous glomerulonephritis, membranoproliferative 
glomerulonephritis, and mesangioproliferative glomerulonephritis).  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  76  
 
Table  7: Potential  Immune -Mediated  Medical  Conditions  
 
Categories  Diagnoses  (as MedDRA  Preferred  Terms)  
Cardiac  Disorders:  Autoimmune  myocarditis/cardiomyopathy.  
Myocarditis  and/or  pericarditis.  
Skin Disorders:  Alopecia areata, psoriasis, vitiligo, Raynaud’s phenomenon, erythema nodosum, 
autoimmune bullous skin diseases (including pemphigus, pemphigoid and 
dermatitis  herpetiformis),  cutaneous  lupus  erythematosus,  morphoea,  lichen  planus, 
Stevens -Johnson syndrome.  
Hematologic  Disorders:  Autoimmune  hemolytic  anemia,  immune  thrombocytopenia,  antiphospholipid 
syndrome, thrombocytopenia.  
Metabolic  Disorders:  Autoimmune  thyroiditis,  Basedow’s  disease,  Hashimoto  thyroiditis,  diabetes 
mellitus type 1, Addison’s disease.  
Other  Disorders:  Goodpasture  syndrome,  idiopathic  pulmonary  fibrosis,  pernicious  anemia, 
sarcoidosis.  
Abbreviations:  ANCA  = anti-neutrophil  cytoplasmic  antibody;  IgA = immunoglobulin  A; MedDRA  = Medical 
Dictionary for Regulatory Activities.  
Source:  Adapted  from  Tavares  2013 . 
Complications  specific  to COVID -19 are listed  in Table  8. The list is not intended  to be 
exhaustive, nor does it exclude the possibility that other diagnoses may be AESIs.  
 
Table  8: Adverse  Events  Representing  Complications  Specific  to COVID -191 
 
Categories  Diagnoses  (as MedDRA  System  Organ  Class/Preferred  Term)  
Respiratory/Infectious  Disorders:  ARDS,  pneumonitis,  septic  shock -like syndrome.  
Cardiac  Disorders:  Acute  cardiac  injury,  arrhythmia,  myocarditis,  pericarditis  (including 
myopericarditis).  
Coagulopathy:  Deep  vein thrombosis,  myocardial  infarction,  stroke.  
Renal  Disorders:  Acute  kidney  injury.  
Hematologic  Disorders:  Thrombocytopenia,  septic  shock -like syndrome.  
Inflammatory  Disorders:  Cytokine  Release  Syndrome2 related  to COVID -19 infection,  multisystem 
inflammatory syndrome in children (MIS -C). 
Neurologic  Disorders:  Generalized  convulsions.  
Abbreviations:  ARDS  = acute  respiratory  distress  syndrome;  COVID -19 = coronavirus  disease  2019;  DAIDS  = 
Division of AIDS; MedDRA = Medical Dictionary for Regulatory Activities.  
1. COVID -19 manifestations  associated  with more  severe  presentation  and decompensation  with consideration 
of enhanced disease potential. The current listing is based on Coalition for Epidemic Preparedness 
Innovations /Brighton Collaboration Consensus Meeting (12/13 March 2020) and expected to evolve as 
evidence accumulates ( Lambert 2020 ). 
2. Cytokine  release  syndrome  is a disorder  characterized  by nausea,  headache,  tachycardia,  hypotension,  rash, 
and/or shortness of breath ( DAIDS 2017 ). 
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  77  
 
APPENDIX 2:  TOXICITY  GRADING  SCALE  FOR  CLINICAL  ABNORMALITIES 
(LOCAL AND GENERAL SYSTEMIC REACTOGENICITY AND 
VITAL SIGNS)  
 
Table 9:  Modified  FDA  Toxicity  Grading  Scale  for Clinical  Abnormalities  (Local  and 
General Systemic Reactogenicity)  
 
Local  Reaction  to Injectable  Product  
  
Mild 
(Grade  1)  
 
Moderate  (Grade  2)  
Severe 
(Grade  3) Potentially  Life 
Threatening 
(Grade 4)  
Pain Does  not interfere  with 
activity  Repeated  use of non- 
prescription pain 
reliever  >24 hours  or 
interferes with 
activity  Significant;  any use 
of prescription  pain 
reliever  or prevents 
daily activity  Requires  ER visit or 
hospitalization  
Tenderness  Mild  discomfort  to 
touch  Discomfort  with 
movement  Significant 
discomfort  at rest Requires  ER visit or 
hospitalization  
Erythema/rednessa 2.5 − 5 cm 5.1 − 10 cm >10 cm Necrosis  or 
exfoliative 
dermatitisb 
Induration/swellinga 2.5 − 5 cm 5.1 − 10 cm >10 cm Necrosisb 
Systemic  (General)  
  
Mild 
(Grade  1)  
 
Moderate  (Grade  2)  
Severe 
(Grade  3) Potentially  Life 
Threatening 
(Grade 4)  
Feverc (°C) 
(°F) 38.0 − 38.4 
100.4  − 101.1  38.5 − 38.9 
101.2  − 102.0  39.0 − 40 
102.1  − 104 >40 
>104  
Nausea/vomiting  Does  not interfere  with 
activity or  
1 − 2 episodes/24  hours  Some  interference 
with activity or  
>2 episodes/24  hours  Prevents daily 
activity, or requires 
IV hydration  outside 
of hospital  Requires  ER visit or 
hospitalization  
Headache  Does  not interfere  with 
activity  Repeated  use of non- 
prescription pain 
reliever  >24 hours  or 
interferes with 
activity  Significant;  any use 
of prescription  pain 
reliever  or prevents 
daily activity  Requires  ER visit or 
hospitalization  
Fatigue/Malaise  Does  not interfere  with 
activity  Some  interference 
with activity  Significant,  prevents 
daily activity  Requires  ER visit or 
hospitalization  
Myalgia  Does  not interfere  with 
activity  Some  interference 
with activity  Significant,  prevents 
daily activity  Requires  ER visit or 
hospitalization  
Arthralgia  Does  not interfere  with 
activity  Some  interference 
with activity  Significant,  prevents 
daily activity  Requires  ER visit or 
hospitalization  
a The measurements  should  be recorded  as a continuous  variable.  
b These  events  are not participant  reported  through  the eDiary  and will be monitored  through  the AE pages  of the 
study database.  
c Oral temperature  if participant  collected,  sites may collect  temperature  using  local  clinic  practices/devices.  
Toxicity  grade  will be derived.  
Source:  FDA  2007  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  78  
 
Table  10: FDA  Toxicity  Grading  Scale  for Clinical  Abnormalities  (Vital  Signs)  
 
 Mild 
(Grade  1) Moderate 
(Grade  2) Severe 
(Grade  3) Potentially  Life Threatening 
(Grade 4)  
Tachycardia  (bpm)  101 – 115 116 – 130 > 130 ER visit or hospitalization  for arrhythmia  
Bradycardia  (bpm)a 50 – 54 45 – 49 < 45 ER visit or hospitalization  for arrhythmia  
Hypertension  (systolic) 
(mm Hg)  141 – 150 151 – 155 > 155 ER visit or hospitalization  for malignant 
hypertension  
Hypertension  (diastolic) 
(mm Hg)  91 – 95 96 – 100 > 100 ER visit or hospitalization  for malignant 
hypertension  
Hypotension  (systolic) 
(mm Hg)  85 – 89 80 – 84 < 80 ER visit or hospitalization  for 
hypotensive shock  
Respiratory Rate 
(breaths  per minute)  17 – 20 21 – 25 > 25 Intubation  
Note:  Participant  should  be at rest for all vital sign measurements.  
a When  resting  heart  rate is between  60 – 100 bpm.  Use clinical  judgement  when  characterizing  bradycardia 
among some healthy participant populations (eg, conditioned athletes).  
Source:  FDA  2007  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  79  
 
APPENDIX  3: ASSESSMENT  OF COVID -19 SEVERITY  
 
Table  11: COVID -19 Severity  Grading  Criteria  
Grade  Criteria  
Mild  ≥ 1 of the following:  
• Fever  (defined  by subjective  or objective  measure,  regardless  of use of anti-pyretic 
medications)  
• New  onset  cough  
≥ 2 additional  COVID -19 symptoms:  
• New  onset  or worsening  of shortness  of breath  or difficulty  breathing  compared  to baseline.  
• New  onset  fatigue.  
• New  onset  generalized  muscle  or body  aches.  
• New  onset  headache.  
• New  loss of taste or smell.  
• Acute  onset  of sore throat,  congestion,  or runny  nose.  
• New  onset  nausea,  vomiting  or diarrhea.  
Moderate  ≥ 1 of the following:  
• High  fever  (≥ 38.4°C)  for ≥ 3 days (regardless  of use of anti-pyretic  medications,  need  not be 
contiguous days).  
• Any evidence  of significant  lower  respiratory  tract infection  (LRTI):  
• Shortness  of breath  (or breathlessness  or difficulty  breathing)  with or without  exertion 
(greater than baseline).  
• Tachypnea:  24 to 29 breaths  per minute  at rest. 
• SpO 2: 94% to 95% on room  air. 
• Abnormal  chest  X-ray or chest  computerized  tomography  (CT)  consistent  with pneumonia  or 
LRTI.  
• Adventitious  sounds  on lung auscultation  (eg, crackles/rales,  wheeze,  rhonchi,  pleural  rub, 
stridor).  
Severe  ≥ 1 of the following:  
• Tachypnea:  ≥ 30 breaths  per minute  at rest. 
• Resting  heart  rate ≥ 125 beats  per minute.  
• SpO 2: ≤ 93% on room  air or PaO 2/FiO 2< 300 mmHg.  
• High flow oxygen (O 2) therapy or non -invasive ventilation (NIV)/non -invasive positive 
pressure  ventilation  (NIPPV)  (eg, continuous  positive  airway  pressure  [CPAP]  or bilevel 
positive airway pressure [BiPAP]).  
• Mechanical  ventilation  or extracorporeal  membrane  oxygenation  (ECMO).  
One or more  major  organ  system  dysfunction  or failure  to be defined  by diagnostic  testing/clinical 
syndrome/interventions, including any of the following:  
• Acute  respiratory  failure,  including  acute  respiratory  distress  syndrome  (ARDS).  
• Acute  renal  failure.  
• Acute  hepatic  failure.  
• Acute  right  or left heart  failure.  
SARS -CoV -2 rS Vaccines 
Novavax  Study  Protocol  2019nCoV -314 Amendment  2 v4.0 
Confidential  Page  80  
 
 
Table  11: COVID -19 Severity  Grading  Criteria  
Grade  Criteria  
 • Septic  or cardiogenic  shock  (with  shock  defined  as systolic  blood  pressure  [SBP]  < 90 mm 
Hg OR diastolic  blood  pressure  [DBP]  < 60 mm Hg). 
• Acute  stroke  (ischemic  or hemorrhagic).  
• Acute  thrombotic  event:  acute  myocardial  infarction  (AMI),  deep  vein thrombosis  (DVT), 
pulmonary embolism (PE).  
• Requirement  for: vasopressors,  systemic  corticosteroids,  or hemodialysis.  
• Admission  to an intensive  care unit (ICU).  
• Death.  
 